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Tetracycline (TC) and its derivatives, including 50(-hydroxytetracycline 
(OTC), 60(-deoxy-50(-hydroxytetracycline (DOTC), 6-demethyl-7-chloro 
tetracycline (DMTC) and 7-chlorotetracycline (CTC), are the antibiotics with 
known phototoxic and hepatotoxic side-effects. These drugs after ingestion are 
solubilized in guts and transported to the target sites through blood, bound to 
serum proteins. In serum, albumin is the most abundant carrier protein involved in 
the transport and deposition of a variety of endogenous and exogenous ligands. 
Owing to the structural similarity of tetracyclines with anthracyclines, a group of 
potent antitumor antibiotics, it is presumed that the tetracyclines may also interact 
with biological macromolecules. This study is based on the premise that 
tetracyclines with their planar naphthacene ring system and characteristic 
functional groups, effectively interact with the proteins and DNA, and inflict 
significant structural alterations and/or fragmentation in these biological 
macromolecules. However, certain fundamentally important aspects encompassing 
the (i) stoichiometry of tetracycline-albumin and -DNA binding, (ii) nature and 
extent of these interactions, and (iii) effect of drug binding on macromolecular 
stability and integrity are not well understood. To address these issues of 
pharmacological and toxicological importance, the in vitro studies using analytical 
techniques such as intrinsic fluorescence quench titration and circular dichroism 
(CD) were performed. Besides, the potential of various tetracycline derivatives for 
generating superoxide anion (O2'") and hydroxyl ("OH) radicals upon 
photoexcitation was quantitatively assessed. Tetracycline-induced protein 
fragmentation was ascertained by SDS-polyacrylamide gel electrophoresis and 
measuring the acid soluble amino groups and carbonyl groups released from 
treated bovine serum albumin (BSA), used as a model protein. Similarly, the 
damage in DNA was monitored using sensitive techniques such as hydroxyapatite 
chromatography, Si nuclease hydrolysis, alkaline hydrolysis, plasmid nicking 
assay, alkaline unwinding assay, and spectrofluorometric and CD analysis. 
The protein fluorescence data clearly demonstrated that the binding of 
tetracyclines quenched the intrinsic fluorescence of albumin to a variable extent. 
The binding isotherms suggested the presence of at least one to four binding sites 
on albumin for different tetracycline derivatives. Competitive binding with the 
marker ligands, specific for site-I and -II of BSA, elucidated site-I with in 
subdomain IIA of albumin as a primary binding site for tetracyclines. The 
Scatchard analysis revealed the binding affinities (Ka) and capacities (n) for TC, 
DOTC, OTC, DMTC and CTC as 4.6 x 10^ 3.4 x 10^ 2.1 x 10^ 1.3 x 10^  and 
0.95 x 10^  litre/mole and 3.6, 1.3, 2.1, 3.4 and 2.9, respectively. The presence of 
metal ions, specifically Cu (II) augmented the interaction of tetracyclines with 
albumin. Also the far-UV CD spectra of BSA in the range of 200-250 nm at 
varying concentrations (O.l-I.O mM) of tetracyclines in presence of 100 [iM Cu 
(II) ions exhibited concentration dependent change in protein ellipticity. The mean 
residue ellipticity (MRE222) of protein upon incubation with tetracycline 
derivatives decreased in the order as TC>DOTC>OTC>DMTC>CTC. The 
significant reduction in MRE reflects the alterations in protein helicity. The overall 
loss in protein helicity was determined to be 25% with TC followed by 23.6, 21.7, 
v i 
19.2 and 18.1% with the derivatives DOTC, OTC, DMTC and CTC, respectively. 
Indeed, the high affinity binding of tetracyclines with BSA signifies drug stability. 
However, the induced conformational changes in albumin structure at higher 
tetracyclines concentration specifically in presence of metal ions exerts damaging 
effect on carrier protein. 
Irradiation of tetracyclines with white light in aqueous solution triggered 
photooxidation and engendered significant amounts of reactive oxygen species 
(ROS) under in vitro conditions. A dose dependent relationship was ascertained 
between the free radical production and tetracycline photoexcitation. Comparative 
analysis revealed differential production of ROS with the photosensitized 
tetracycline derivatives having different functional groups. Significant reduction in 
the amount of free radicals produced in the presence of scavengers such as 
mannitol, ethanol, dimethylsulfoxide (DMSO) and superoxide dismutase (SOD) 
confirmed the generation of "OH and O2" radicals upon tetracycline 
photoexcitation. Addition of transition metal ion, Cu (II) enhanced the production 
of tetracycline-induced free radicals to a significant extent. Treatment of BSA with 
photoexcited tetracyclines in concentration range of 0.1 to 1.0 mM resulted in the 
dose dependent fragmentation of protein. An estimated release of 313 i^M acid 
soluble amino groups and 220 |xM carbonyl groups from albumin treated with 1 
mM tetracyclines in combination with 100 |iM Cu (II) ions corroborated these 
findings. The tetracycline-Cu (II) induced protein fragmentation was further 
validated by SDS-polyacrylamide gel electrophoresis. The plausible reason for the 
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release of protein degradation products could be the peptide bond hydrolysis 
and/or chain scission at (X-carbon position. Substantial reduction in the extent of 
protein fragmentation in presence of 10 mM mannitol unequivocally suggested the 
role of "OH radicals in tetracycline-Cu (II) catalyzed protein fragmentation. 
However, no SOD mediated quenching effect was noticed. Thus, the production of 
tetracycline-induced free radicals and consequent protein fragmentation is 
envisaged as critical determinants in provoking tetracycline-induced cytotoxic 
responses. 
To assess the genotoxic potential of tetracyclines, it is essential to 
understand the binding properties with DNA and consequent damage in treated 
DNA. Similar to albumin-drug binding studies, the interactions of calf thymus 
DNA with tetracycline and its derivatives were monitored by spectrofluorometric 
and CD analysis. In this study, unlike the protein fluorescence measurements, the 
tetracyclines intrinsic fluorescence properties were exploited. At their respective 
emission maxima, the fluorescence intensities of tetracyclines were found to be 
decreased upon interaction with DNA at varying molar ratios. The percent 
fluorescence quenching were estimated to be 64, 47, 36.5, 15 and 11% for TC, 
CTC, DMTC, OTC and DOTC, respectively. Thus, the stronger interactions of 
TC, CTC and DMTC with DNA molecules are suggested. Based on Scatchard 
analysis, the binding affinity (Kg) of TC was determined to be 1.16 x 10^  litre/mole 
with native calf thymus DNA. Similarly, the Ka values for CTC-DNA and DMTC-
DNA complexes were determined to be 3.4 x 10^  and 3.0 x 10^  litre/mole. 
V l X l 
respectively. The interactions of tetracyclines with DNA were found to be strongly 
dependent on the conformational stability of DNA. The perturbation of DNA 
structure by changing the ionic environment decreased its interaction with 
tetracyclines. The results also clearly suggested the role of both the intercalative 
and electrostatic interactions in the binding of tetracyclines with DNA. 
Furthermore, the presence of metal ions, specifically Cu (II) augmented the 
interaction of tetracyclines with DNA. The CD spectra of tetracycline showed a 
characteristic positive band at 294 nm and two negative bands at 326 and 248 nm. 
Addition of Cu (II) ions to TC solution at a TC-Cu (II) molar ratio of 1:2 resulted 
in a red shift by 12 nm. The molar ellipticity (0) at the respective positive and 
negative peaks changed to a significant extent with the addition of DNA due to the 
formation of the TC-Cu (II)-DNA ternary complex. The data clearly demonstrated 
the DNA damaging potential of tetracyclines both in the presence and absence of 
Cu (II) ions. 
Based on the available data, it is deduced that the interaction of 
tetracyclines with DNA resulted in alkylation at N-7 and N-3 positions of adenine 
and guanine bases. These methyl groups could be spontaneously transferred from 
C-6 position of the aromatic ring-C and nitrogen of the ring-A of tetracycline 
molecule. The methylation at adenine and guanine will result in GC to AT and AT 
to GC mispairing with a distinct possibility of apurinic/apyrimidinic site 
formation. An increased susceptibility of tetracycline-Cu (II) treated DNA to 
alkaline hydrolysis also suggested tetracycline-Cu (II) induced DNA alkylation 
and formation of apurinic and/or apyrimidinic sites. The treatment of tetracycline 
I X 
modified DNA with O.IM and 0.5M NaOH resulted in 62 and 76% hydrolysis 
compared to untreated parallel controls. Also, a significant release of acid soluble 
nucleotides from tetracycline modified DNA upon incubation with Si nuclease 
ascertained the formation of single stranded regions in the DNA. The alkaline 
unwinding assay clearly demonstrated the formation of- 6.0 strand breaks per unit 
DNA at 1:10 DNA nucleotide:TC molar ratio in presence of 100 |iM Cu (II) ions. 
At a similar Cu (II) concentration, a progressive transformation of covalently 
closed circular (form I) plasmid pBR322 DNA to form (II) and (III) was noticed 
with increasing tetracycline concentrations. The hydroxyapatite chromatography 
data also revealed almost 50% denaturation of duplex DNA at 1:10 DNA:TC 
molar ratio. 
Furthermore, the stoichiometric data based on Job plot analysis revealed the 
reduction of 3.5 Cu (II) ions to Cu (I) with one tetracycline molecule. It is 
envisaged that the formation of Cu (I) from TC-Cu (II) complex will be critical for 
DNA strand breakage, as the formation of strand breaks was significantly inhibited 
in presence of neocuproine, a well known Cu (I) chelator. Most likely, the 
tetracycline in reduced form undergoes oxidation with a transfer of electron to 
either molecular oxygen to form superoxide or to transition metal ion Cu (II). The 
superoxide anions generated can act both as a reductant for transition metal ions or 
as a precursor of hydrogen peroxide. Subsequently, the Fenton-type reaction forms 
•OH radicals due to reaction of reduced copper with hydrogen peroxide leading to 
DNA damage. Studies involving the free radical quenchers such as sodium 
benzoate and mannitol clearly suggested the role of "OH radicals in tetracycline-
Cu (II) induced DNA damage. 
It is, therefore, concluded that tetracyclines bind to both the protein and 
DNA with sufficiently high affinity. The higher binding affinity of tetracycline 
and its derivatives, specifically with serum albumin may enhance the stability and 
potency of these drugs in the body. On the contrary, the excessive drug binding in 
presence of metal ions induces the conformational changes in globular structure of 
albumin. Also, the production of "OH radicals in closed proximity of protein with 
bound tetracycline-Cu (II) results in site-specific cleavage. Increased 
fragmentation of albumin and 'OH radical generation with the addition of Cu (II) 
ions reflects the role of metal ions in augmenting tetracycline-induced toxicity. 
Moreover, the data on tetracycline-DNA interactions revealed that tetracycline can 
act both as intercalator and surface binder involving the electrostatic and 
hydrophobic forces. Irrespective of the nature of interaction, the binding of 
tetracyclines caused perturbation in the secondary structure of DNA. These 
tetracycline-Cu (II) induced structural alterations and/or fragmentation of proteins 
and DNA could be detrimental under intracellular conditions. Based on in vitro 
observations, it is surmised that the administration of tetracyclines in individuals, 
particularly those with defective copper metabolism and DNA repair pathways, 
may result in severe macromolecular damage and augmentation of cytotoxic and 
mutagenic responses. 
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Tetracyclines are a group of antibiotics derived from naphthacene ring 
(l,4,4a,5,5a,6,11,12a octahydronaphthacene) with a characteristic distribution of 
double bonds and substitutions. These antibiotics have been grouped into two 
main classes based on their mode of action (Chopra, 1994). Classical tetracyclines 
(class I) include tetracycline, chlorotetracycline, doxycycline and minocycline, 
which are regarded as bacteriostatic agents. However, class II or atypical 
tetracyclines, including anhydrotetracycline, 6 thiatetracycline and chelocardin, 
are bactericidal agents and promote cell lysis (Oliva et al., 1992; Chopra, 1994). In 
general, the class I tetracyclines constitute a group of broad-spectrum antibiotics. 
They are closely related in terms of their chemical structure and antimicrobial 
activity but differ with respect to their pharmacokinetic properties. These 
tetracyclines have been reported to inhibit (a) protein synthesis by preventing the 
binding of aminoacyl-tRNA to the ribosome (Lucas-Lenard & Haenni, 1968; Gale 
et al., 1981) (b) self-splicing of group I and group II intron of Cox/gene of yeast 
DNA (Liu et al., 1994), and (c) self-cleavage reaction of human delta virus 
ribozymes (Rogers et al., 1996). They bind covalently to 30 S subunit of ribosome 
and polyuridylic acid (Connamacher & Mandel, 1965; Reboud et a/., 1982; 
Goldman et a/., 1983). They also cause alterations in the cytoplasmic membrane, 
resulting in leakage of nucleotides and other compounds from the cell (Pato,1977). 
At higher concentrations, class I tetracyclines also induce photohemolysis of 
human erythrocytes by an oxygen independent mechanism (Nilsson et al., 1975). 
The antibiotic chlorotetracycline (CTC) was the first to be isolated from a 
soil microorganism Streptomyces aureofaciens (Duggar et al, 1948), followed by 
oxytetracycline (OTC), derived from S. rimosus (Finlay et al., 1950). 
Subsequently, tetracycline (TC) was synthesized by catalytic hydrogenation of 
chlorotetracycline (Boothe et al., 1953). All tetracyclines have a common four 
benzene ring structure with distinguishing individual ring modifications as shown 
in Figure 1. The elucidation of the TC structure has greatly helped in structural 
manipulations and development of newer derivatives. For instance, CTC has 
chlorine substituted at C-7 position and OTC has a hydroxyl group at C-5 position 
of tetracycline. The removal of a methyl group from C-6 position of CTC yields 
demeclocycline (DMTC). The elimination of a hydroxyl group from the C-6 
position of TC yields doxycycline (DOTC) (Jonas et al., 1984). 
CiMjC OH HjCvj^^CHj 
CONH, 
OH 0 OH 0 
H,C OH off > " ^ ' ' ' 
^ ^ . ' O H Y "CONH, 
OH 0 OH 0 
Tetracycline Chlorotetracycline 
CH,HO''^"N-^"' 
Oxytetracycline 
OHn CONH, 
OH 0 OH 0 
Doxycycline 
OH 0 OH "o 
Demeclocycline 
Figure 1. Structures of tetracyclines (Adapted from Egle, 1995). 
Tetracyclines are amphoteric substances with three pK values. The pKa 
values are attributed to the tricarbonyl system of ring A (pK]), the 
dimethylammonium function of ring A (pK2), and the phenolic p-diketone system 
in the C-10-11-12 region (pKj) (Stephens et al., 1956). Based on the pKa values, 
the tetracyclines exist as a zwitterion at neutral pH and monoanion above pH 8.0. 
The monoanions are known to be the reactive species and have an isoelectric point 
at about pH 5.0 (Mitscher, 1999). It has been reported that alpha-stereo orientation 
of the C-4 dimethylamino-moiety of the tetracyclines is essential for their 
biological activity. The presence of the tricarbonyl system of ring A allows 
enolization, involving loss of the C-4 hydrogen as shown in Figure 2. However, 
reprotonation from the top of the enol regenerates tetracycline, whereas from the 
bottom produces inactive 4-epitetracycIine. At equilibrium, the mixture consists of 
nearly equal amounts of the two diastereomers (Mitscher, 1999). The removal of 
hydroxyl group from C-6 position reduces tetracycline degradation (Barza et ai, 
1975;Grassi&Sabath, 1981). 
\ ^N(CH3)2 
OH 
CONH2 
Tetracycline (active) ^ "' 4-Epitetracycline (inactive) 
OH OH O ^"^ OH OH O ° " 
Tetracycline (active) Anhydrotetracycline (inactive) 
Figure 2. Stereochemistry and epimerization of tetracycline 
(Adapted from Mitscher, 1999). 
Biosynthesis of tetracycline 
Biosynthesis of tetracycline occurs by a complex sequence of 
transformations involving condensation of malonamoyl coenzyme A and eight 
acetate units. The process is quite analogous to fatty acid biosynthesis, except that 
most of the carbonyl groups remain in the molecule and self condense in a 
controlled way to produce the partially reduced naphthacene nucleus (Figure 3). A 
sequence of reductions, oxidations, methylations, aminations and dehydration 
completes its biosynthesis (Mitscher, 1999). 
/ \ 
1*CI} [^CH3)(0] fH] [ + 0 ] (01 - . - [NH3] [(CH3)2] 
H \ V ^ ^ 
O ' V ^^^ . . - - -CH3 . . . -CH3 
[H] - ^ HaC 
•0 HO •0 HO 
; C H 3 . _ _ ^CH3.,_ ^CH3.._ ^CH2 
• " 1 \ • • ' 
M H 0 - „ HO-'J^ ^ H O - ^ 
O 0 O \ O 
[0] 
Figure 3. Biosynthesis of tetracycline (Mitscher, 1999). 
Mechanism of action in bacteria 
Tetracyclines enter the bacterial cells by a combination of passive diffusion 
through hydrophilic channels formed by the porin proteins of outer cell membrane, 
and energy-dependent active transport mechanism that pumps all tetracyclines 
through the inner cytoplasmic membrane (Chopra & Howe, 1978). All 
tetracyclines have been found to be highly effective against Gram-positive and 
Gram-negative bacteria, including penicillin insensitive Tubercle bacillus, 
Rickettsiae and the Clamydial species (Osol & Pratt, 1973). The tetracyclines 
inhibit bacterial protein synthesis by binding to the 3OS ribosomes, preventing 
access of aminoacyl tRNA to the acceptor site on the mRNA-ribosome complex 
(Hogenaur & Tumowsky, 1972; Pato, 1977; Hlavka & Boothe, 1985). This action 
prevents the addition of new amino acids to the growing polypeptide chain. 
Tetracycline-induced alterations in cytoplasmic membrane lead to the leakage of 
intracellular pool of nucleotides, amino acids and other compounds from the cell. 
Pato (1977) has also reported inhibition of DNA replication at higher tetracycline 
concentrations. These antibiotics also exhibit chelating properties and reportedly 
chelates calcium, magnesium, manganese and aluminium ions required for 
enzymatic activity in the cells (Caswell & Hutchison, 1971; Schneider et al., 
1983). 
Mechanism of action in humans 
Absorption 
All orally administered tetracyclines are sufficiently absorbed in 
gastrointestinal tract. However, the rate and extent of absorption varies among the 
individuals. The percentage of an oral dose that is absorbed is lowest for CTC 
(30%), intermediate for OTC, DMTC and TC (60% to 80%), and higher for 
DOTC (93%) and minocycline (100%) (McDonald et al, 1973; Egle, 1995). Food 
and milk significantly decrease the absorption of TC, CTC, OTC and DMTC 
without significantly affecting the MC and DOTC absorption (Fabre et al., 1971; 
Cunha et al., 1982). Antacids containing di- and -trivalent cations such as 
aluminium, calcium, magnesium and iron form poorly soluble complexes with the 
tetracyclines and interfere with gastrointestinal absorption. About 20 to 50% of the 
drug remains chelated with the cations and is eliminated in the stool (Barr et al., 
1971; Elliott & Armstrong, 1972; Neuvonen, 1976). Absorption of TC has been 
correlated with its plasma level after administration. It has been reported that TC, 
after an oral dose of 500 mg, reaches to the serum within 30 min, and attains a 
peak concentration of 4 i^ g/ml within 1 to 3 h. Similarly, CTC at a similar dose, 
reaches to a serum level of only 1 |ig/ml. Both minocycline and DOTC at 200 mg 
oral loading dose, reach to a detectable serum level within an hour. The 
intravenous administration of tetracyclines have also been shown to produce 
almost similar serum levels (Holvey et al, 1969; Lang, 1971; Cartwright et al., 
1975; Leiboautz et al, 1978). The serum half-life for TC, OTC, DMTC, DOTC 
and CTC has been reported to be 10, 9, 15, 15 and 7 h, respectively (Jonas et al., 
1984). The pharmacokinetic characteristics of some of the commonly used 
tetracyclines are summarized in Table 1. 
Distribution 
Tetracyclines are well distributed in most parts of the body tissues and 
fluids, including liver, spleen, bone marrow, bile and cerebrospinal fluid (CSF). 
The concentration of TC in CSF has been reported to be about one-tenth of the 
simultaneous serum concentration (Finland & Garrod, 1960). The drugs also cross 
the placental barrier and enter the fetal circulation and amniotic fluid in 
appreciable amounts. The concentrations of TC in umbilical-cord plasma and 
amniotic fluid reaches to 60% and 20%, respectively, of the concentration in blood 
circulation of the mother. Transport of these antibiotics across the lipid rich cell 
membrane is highly dependent on its liposolubility index. However, more 
lipophilic tetracyclines get accumulated in body tissue and have been detected 
even in the milk of nursing mothers (Kapusnik-Uner et al., 1996). The 
Table 1 
Pharmacokinetic properties of tetracyclines 
Drugs 
TC 
CTC 
OTC 
DMTC 
DOTC 
MC 
GI 
Absorption 
(%) 
80 
30 
60 
70 
93 
100 
T'/2 
(h) 
10 
07 
09 
15 
15 
17 
Excretion 
in urine 
(%) 
60 
20 
70 
40 
35 
10 
Peak serum 
level 
(Mg/ml) 
2-4 
2.5 
2.0 
1.3 
2-4 
2-4 
Adapted from Jonas et al. (1984) and Egle (1995). 
liposolubility has been reported to be highest for MC followed by DOTC and OTC 
(Egle, 1995). Therefore, the tissues and fluid concentrations vary considerably 
among the members of the tetracycline family. The DOTC and MC penetrate more 
readily into the brain, eye and intestinal epithelium tissues. Concentration as high 
as 30-fold above normal serum level of tetracyclines has been reported in the bile 
of patients with non-obstructive biliary tract disease. Most tetracyclines have also 
been detected in low concentrations in tears and saliva. Concentrations in the 
range 0.6 to 6.5 )ig/ml have been detected in vaginal secretion of woman taking 
250 mg OTC four times a day (Thin et al, 1979). Following an oral dose of 250 
mg TC, three times a day, its level in sputum has been reported to be in the range 
of 0.4 to 2.6 ^g/ml (Ruhen & Tandon, 1976). Similarly, the concentration of 
DOTC in the thoracic duct lymph and peritoneal fluid are maintained at about 
75% of simultaneous serum levels (Anderson et al., 1976), and those in colonic 
tissue exceeds the serum level (Hojer & Wetterfors, 1976). The concentration of 
DOTC in prostatic tissue also reaches 60% of the serum concentration (Eliasson & 
Malmborg, 1976; Oosterlinck et al., 1976). Lower concentrations of DOTC are 
reported in bone (Dombusch, 1976), skin, subcutaneous fat and tendon tissue, 
however, the level in muscles has been determined to be relatively higher (Gnarpe 
etal.,\916). 
Excretion 
The primary route of elimination for most tetracyclines is through the 
kidney (Dimmling, 1960). These drugs are reported to be concentrated in liver and 
also excreted through bile into the intestines (Barza et al., 1975). Elimination 
through the intestinal tract occurs even when the drugs are given parenterally. 
Amongst all the tetracyclines, minocycline is an exception and is significantly 
metabolized by the liver (McDonald et al., 1973). Since renal clearance of these 
drugs is by glomerular filtration, their excretion is significantly affected by the 
renal function status of the patient when administered both orally and 
intravenously. Almost 20% to 60% of TC is excreted in urine during the first 24 h, 
and 10% to 35%) of OTC excreted within 30 min. Decreased hepatic function or 
obstruction of the common bile duct reduces the biliary excretion of these agents, 
resulting in longer half-lives and higher plasma concentrations. Because of their 
enterohepatic circulation, the tetracyclines may be present in the body for a long 
time after cessation of therapy (Kapusnik-Uner et al., 1996). 
Tetracyclines at increased doses may also cause a catabolic state resulting 
in acidosis and increasing azotemia when administered to patients with chronic 
renal failure (Womola, 1977). The elimination of DOTC following parenteral 
administration involves drug secretion into the gastrointestinal tract, where it 
forms a stable inactive chelated complex that is excreted in the stool. In the 
patients with renal dysfunction, elimination of tetracyclines via the gastrointestinal 
tract increases (Bartlett et al., 1974). 
Intracellular toxicity 
Tetracyclines are associated with numerous adverse effects, ranging from 
hypersensitivity reactions to direct toxic effects. The most common side-effects of 
these drugs are gastrointestinal irritation, epigastric burning and distress, 
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abdominal discomfort, nausea and vomiting. Also, esophagitis and esophageal 
ulcers have been reported (Winckler, 1981; Amendola & Spera, 1985) in 
association with pancreatitis (Elmore & Rogge, 1981). 
Lepper et al. (1951) have first demonstrated TC-induced hepatotoxicity 
when intravenous dose exceeds 1-2 g per day. In susceptible target groups, the 
pregnant woman exhibits severe tetracycline-induced hepatic damage (Schultz et 
al, 1963; Kunelis et al, 1965), and some times even irreversible renal failure 
(Schultz et al, 1963; Whalley et al, 1964). The pathological changes are 
proportional to the degree of renal impairment and to the dose and duration of TC 
administration (Schultz et al, 1963; Whalley et al, 1964). In fetal liver, extensive 
fine vacuolar fatty infiltration occurs in addition to pathological changes in the 
pancreas, kidney and brain (Whalley et al, 1964; Kunelis et al, 1965). 
Tetracylines are also deposited in teeth and bones during the early stages of 
calcification (Kline et al, 1964; Toaff & Ravid, 1966). Binding of tetracyclines to 
bones retards the bone growth in fetuses and young children. Also infants display 
an increase in intracranial hypertension with bulging fontanelles upon TC 
treatment (Cohlan et al, 1963). 
Photosensitivity of tetracyclines 
The photosensitivity of TC with sunlight or UV irradiation is well 
documented (Sandberg et al, 1984; Piette et al, 1986). All tetracyclines 
maximally absorb in near-UV region (365 nm) and undergo photosensitization. 
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The effective wavelength for eliciting phototoxicity in vivo has been reported to be 
between 320-425 nm (Schorr & Monash, 1963; Blank et a/., 1968). The 
tetracycline derivatives are also degraded by near-UV irradiations and yield 
quinone derivative (Davies et al., 1979; Moore et ai, 1983). Differential pulse 
polarographic analysis (Moore et ai, 1983) shows that the first step in 
photodegradation reaction of the TC molecule is a loss of dimethylamino group 
situated at C-4 position. The abstraction of this group leads to the formation of a 
free radical on the TC molecule (Finkelstein et ai, 1980). The photodissociation 
of the dimethylamino group is rapidly followed by a reaction of O2 forming 
peroxide radical at C-4 position (Figure 4). Subsequent Fenton-type 
decomposition of this peroxide radical leads to the production of hydroxyl radicals 
(•OH) (Davies et ai, 1979; Green & Hill, 1984). 
, 0H 
J U L • < 
CH, 
CH, 
CONH, 
H . ^00 
0 
Figure 4. Photochemistry of tetracycline (Adapted from Piette et al., 1986). 
Chemistry of free radical production 
The reduction of oxygen generates reactive intermediates and free radicals 
(Fridovich, 1978; Thomalley & Bannister, 1985). The usual route for metabolism 
of molecular oxygen involves its complete reduction to H2O2 by accepting four 
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electrons (Yu, 1994). However, with one electron reduction, several free radicals 
and H2O2 can be formed as discussed below 
02+e" • 02"~ (superoxide radical) 
O2+H2O • H02- + OH" (hydroperoxyl radical) 
H0*2+e" + H • H2O2 (hydrogen peroxide) 
H202 + e" • -OH +0H" (hydroxyl radical) 
Among the reactive oxygen species (ROS), the superoxide anion (02'~) is 
the first intermediate in the sequential univalent reduction of O2 leading to the 
formation of H2O (Florence, 1990; Harris, 1992). The anion radical is unique, 
since it can lead to the formation of many other reactive species like • OH, H2O2 
and perhydroxyl (HO'2) radicals (Pryor, 1984). The 02*"anion interacts with H2O2 
to generate the singlet oxygen molecules. The most important feature of 02"~ is its 
ability to act as a Bronsted base. Thus in aqueous media, the acid-base equilibrium 
(pKa=4.8) shifts to form a hydroperoxyl radical. In an acidic environment, the 02*~ 
readily generates H2O2. However, at neutral or higher pH, the dismutation of 02"~ 
is catalyzed by superoxide dismutase (Gregory et ai, 1973; Fridovich, 1978). 
Although, H2O2 by definition is not considered an oxygen free radical, it 
nevertheless remains the most extensively studied oxygen metabolite (Harris, 
1992). 
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The dismutation of 02'~ by superoxide dismutase is a major source of 
H2O2. By itself, H2O2 is not reactive enough to oxidize many organic molecules. 
However, there is evidence that H2O2 induce DNA damage (Burdon et al., 1996). 
It is also regarded as a biologically important oxidant, due to its ability to generate 
highly reactive • OH upon interaction with redox-active transition metals (Aruoma 
et al, 1991). The importance of H2O2 is, therefore, placed on the initiation of free 
radical cytotoxicity rather than its chemical reactivity. 
The 'OH radical is the most potent oxidant encountered in biological 
systems. The biological importance of "OH as oxidant was first recognized during 
its generation upon X-ray irradiation. However, the cellular generation of 'OH 
may occur by several routes (Aruoma et al, 1991). The two common and 
important biological reactions include (1) generation by decomposition of H2O2 
via Fenton reaction (Fenton, 1894), and (2) interaction of superoxide with H2O2 
through the Haber-Weiss reaction (Haber & Weiss, 1934). 
Fe^^ + H2O2 • Fe^^+-OH + 0 H " (1) 
02-" + H2O2 • O2 + H2O + -OH (2) 
These radicals can also be generated when the reduced forms of transition metal 
ions such as copper combine with H2O2 (Shi et al., 1994). 
Cu^ + H2O2 • Cu^^  + -OH + OH- (3) 
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Because of its extremely short half-life, the diffusion capacity of 'OH is restricted 
to only about two molecular diameters (Fee & Valentine, 1977). Nevertheless, 
they readily react with a variety of biological macromolecules (Von Sonntag, 
1987; Aruoma & Halliwell, 1991; Dizdaroglu, 1991). 
Proteins and DNA: The target biological macromolecules 
Proteins: 
Serum albumin: As a carrier of endogenous and exogenous ligands 
Serum albumin is located in every tissue and bodily secretions. About 40% 
of the total albumin is found in the circulatory plasma (Peters, 1992) whereas 
remaining 60% is distributed about half in viscera and half in muscle and skin 
(Rabilloud et ah, 1988). The albumin concentration in plasma of an average 
person is about 35-50 g/1, which declines slightly with age (Cooper & Gardner, 
1989) and is lower in newborns (Cartlidge & Rutter, 1986), and as low as 20 g/1 in 
premature infants (Reading et al, 1990). Albumin is produced by liver at a rate of 
0.7 mg/g liver per hour (Peters, 1985). Approximately 4-5%) of albumin is 
replaced by hepatic synthesis daily (Olufemi et al, 1990). The turnover is first 
order with an average half-life of 19 days (Waldmann, 1977). 
Functions of serum albumin 
Albumin performs many vital functions in the body while circulating in 
blood plasma. It is mainly responsible for the maintenance of blood pH and 
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contributes -80% to the colloidal osmotic blood pressure. It is the chief reservoir 
and carrier for long chain fatty acids (Brodersen et al., 1991; Cistola & Small, 
1991), acyl coenzyme A esters (Richards et al, 1990) and mono-acyl 
phospholipids (Robinson et al., 1989). It binds to polyunsaturated fatty acids (Anel 
et al, 1989) and influences the stability (Haeggstrom et al, 1983), biosynthesis 
(Heinsohn et al, 1987) and conversion of prostaglandins (Dieter et al., 1990). It is 
involved in the transport of thyroid hormones (Mendel et al, 1990) and tryptophan 
(Herve et al, 1982) through reversible binding. It modulates the calcium ion 
stimulation of gluconeogenesis. It is also involved in the transport of pyridoxal 
phosphate (Fonda et al, 1991), cysteine and glutathione (Joshi et al, 1987) by 
forming a covalent linkage with these ligands. Albumin is responsible for the 
transport and storage of many therapeutic drugs in the blood stream (Lindup, 
1987). Albumin microspheres are useful carriers of therapeutic agents (Morimoto 
& Fujimoto, 1985). 
Physico-chemical properties 
Physico-chemical properties of BSA are summarized in Table 2. The 
molecular weight of albumins is less than that of most of the other plasma proteins 
and ranges in between 66,000 and 67,000 (Loo et al, 1991). Under neutral 
conditions of pH, albumin has an axial ratio of approximately 2.66 based on the X-
ray crystallography data, which is in agreement with the value of 3.0 obtained 
from the studies of dielectric and birefringence relation times (Moser et al., 1966). 
The solvent-accessible surface and molecular volume are 28, 202 A^ and 88, 249 
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Table 2 
Physico-chemical properties of bovine serum albumin 
Property 
Molecular weight 
Sedimentation Coefficient S°2o, w(S) 
Diffusion Coefficient D°2o, w (dcmVs) 
Partial specific volume, V20 (cm 
Intrinsic viscosity, [r|] 
Fractional ratio, f/fo 
Overall dimensions, A 
Isoelectric point 
E'°''°icm at 280 nm 
Mean residue rotation, [m']233 
(X-helix, (%) 
3-structure, (%) 
%) 
Value 
66,411 
4.5 X 10-'^  
5.9x10"^ 
0.733 
0.041 
1.30 
41.6x140.9 
4.7 
6.67 
8443 
68 
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Reference 
Peters (1992) 
Squireen a/. (1968) 
Wagner & Scheraga (1956) 
Hunter (1966) 
McMillan (1974) 
Creeth(1952) 
Wright & Thompson (1975) 
Longsworth & Jacobsen (1949) 
Pace era/. (1995) 
Moore & Foster (1968) 
Reed eM/. (1975) 
Reed era/. (1975) 
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A^ respectively (Richards, 1985). Hydrodynamically, BSA shows a sedimentation 
coefficient, S°2o, w of 4.5 x 10"'^  S, diffusion coefficient, D°2o,w of 5.9 x 10"^  
cm /^sec (Wagner & Scheraga, 1956; Squire et al., 1968) and partial specific 
volume of 0.733 cc/g (Hunter, 1966). The intrinsic viscosity of the protein has 
been measured as 0.041 cc/g (McMillan, 1974). At physiological pH, the 
calculated net charge per molecule is -17 (Peters, 1985). High charge on the 
protein molecule is responsible for its high solubility in water and a solution as 
concentrated as 30% (w/v) can be prepared (Peters, 1985). The specific absorption 
coefficient, E'°''°icni at 280 nm has been found to be 6.67 (Pace et al, 1995). 
Amino acid composition 
BSA is a single chain protein containing 583 amino acid residues (Peters, 
1992). The amino acid composition of BSA is given in Table 3. The protein 
contains appreciable number of half cystine residue and is rich in acidic amino 
acid residues i.e. aspartic acid and glutamic acid (Brown & Shockley, 1982). It is 
fairly hydrophobic. BSA does not contain any carbohydrate or any other non-
protein moiety. It has low contents of isoleucine, methionine and glycine, and 
contains only two tryptophan residues (Carter & Ho, 1994). 
There are 17 disulfide bridges in albumin and the whole molecule is 
characterized by a unique arrangement of double loops that repeat as a series of 
triplets. They are arranged in a series of nine loop-link-loop structures centered 
around eight sequential Cys-Cys pairs. The conformations of the disulfides are 
primarily gauche-gauche-gauche (C31-S1-S2-C32) with torsion angles clustering 
Table 3 
Amino acid composition of bovine serum albumin 
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Amino acid Residues per mole 
Aspartic acid 
Asparagine 
Threonine 
Serine 
Glutamic acid 
Glutamine 
Proline 
Glycine 
Alanine 
Cystine/2 
Cysteine 
Valine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Histidine 
Lysine 
Tryptophan 
Arginine 
40 
14 
33 
28 
59 
20 
28 
16 
47 
34 
01 
36 
04 
14 
61 
20 
27 
17 
59 
02 
23 
Total 
Calculated % Nitrogen 
Calculated net charge (pH 7.0) 
Calculated Mol. Mass (Da) 
583 
16.4698 
217 
66411.17 
Adapted from Peters, (1996). 
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around ± 80° (He & Carter, 1992). The repetition of these loops in a triplet fashion 
of large-small-large can group these loops into three homologous domains (I, II & 
III) comprising of residues 1-190, 191-382 and 383-583 in the primary sequence 
of albumin (Brown, 1977). The sequence homology between these domains is 18-
25% (Brown, 1977). The charge distribution of BSA at neutral pH for domains I, 
II and III are -11, -7 and +1, respectively (Peters, 1996). 
X-ray structure 
The three dimensional structure of BSA has been determined by X-ray 
crystallography at a resolution of 3.2 A (He & Carter, 1992). Each of the three 
homologous domains (I, II & III) of albumin is further divided into two 
subdomains 'A' and 'B', respectively. The subdomains are extensively cross-
linked by disulfide bridges, which form the basis of the occurrence of 9 loops (3 in 
each domain) in albumin molecule. Albumin structure is predominantly (X-helical 
(Jacobsen, 1972; Sjoholm & Ljungstedt, 1973; McLachlan & Walker, 1977). 
There are 10 principal helices in each domain, hl-h6 for subdomains 'A' and h7-
hlO for subdomain 'B'. Further, the six subdomains share a common helical motif, 
which corresponds to the amino acids encompassed with in the double disulfide 
loops 1, 3, 4, 6, 7 and 9 where in each motif is related by a pseudo two-fold axis 
(1:168°, 11:163°, 111:175°) (Carter & Ho, 1994). Distinct differences between 
subdomains 'A' and 'B' also exist. The subdomain 'A' supplement the three helix 
bundle on the C-terminal side with an additional but smaller disulfide double loop 
(loops 2, 5 and 8) to form a small globin-like fold that is extensively cross-linked 
20 
by four disulfide bridges. The subdomain 'B' supplements the helical motif on the 
N-terminal side with a conformationally extended polypeptide to create a folding 
topology that closely resembles a simple up-down helical bundle. Subdomains 'A' 
and 'B' assemble through hydrophobic helix packing interactions primarily 
involving h2, h3 and h8. Additionally, the subdomains are linked together by a 
presumed flexible extension of polypeptide encompassing residues Lysioe-Glung, 
Glu292-Val3i5 and Glu492-Ala5ii in the domains I, II and III, respectively. Domains 
I-II and II-III in turn are connected through extensions of hlO(I)-hl(II) and 
hlO(II)-hl(III), respectively, creating the two longest helices (Carter & Ho, 1994). 
Albumin-ligand interactions 
A variety of endogenous and exogenous ligands are known to bind serum 
albumin (Fehske et A/.,1981; Kragh-Hansen, 1985; Curry et ai, 1998). Ligand 
binding properties of albumin has been extensively studied in order to get an 
understanding about the role of albumin as a vehicle for biologically important 
ligands as well as about its tertiary structure (Lindup, 1987). A variety of 
substances differing in structure and chemical properties are known to bind 
albumin in a reversible manner and their association constants ranges from 10^  to 
10^  M-' (Peters, 1985; 1992; Kragh-Hansen, 1990; Carter & Ho, 1994). Ligands 
can be viewed either as endogenous or exogenous and may be cationic, neutral or 
anionic in nature. Some of the cationic ligands known to bind albumin are small 
inorganic ions such as Ca^ "^ , (Fogh-Andersen, 1977), Cu^"*^  (Lau et al., 1974), Ni ^ 
(Callan & Sunderman, 1973) Cd^ ,^ Zn^ ^ (Goumakos et al., 1991; Bal et al. 
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1994; Zhou et al, 1994 ), Hg^ ^ (Sarkar, 1983), Au^ ^ (Shaw, 1979), Al^ ^ (Trapp, 
1983), etc. Among the endogenous substances, various organic anions such as 
long chain fatty acids (Brodersen & Ebbesen, 1983; Spector, 1986), bilirubin 
(Brodersen, 1979; Tayyab & Qasim, 1987; Mir et al, 1992) and amino acids 
like tryptophan (Sollene et al, 1981; Zhang et al, 1993) are important from 
biological point of view. In addition to these ligands, a large number of drugs are 
also known to bind to albumin via a few high affinity binding sites and several 
sites of much lower affinity, after their administration into the blood stream. These 
include tetracycline (Khan et al, 1998), adriamycin (Trynda-Lemiesz & 
Kozlowski, 1996), indomethacin (Hultmark, et al, 1975; Trivedi et al, 1999), 
ibuprofen (Whitlam et al, 1979), warfarin (Sudlow et al, 1975; Moreno et al, 
1999), diazepam (Muller & Wollert, 1979), digitoxin (Fehske et al, 1981), 
carprofen (Rahman et al, 1993), salicylic acid (Taira & Terada, 1985), 
cephalosporins (Tawara et al, 1992), diclofenac (Chamouara et al, 1985) and 
various anti-cancer drugs including camptothecin, topotecan (Burke & Mi, 1994) 
and cisplatin (Neauh et al, 1998). In addition to endogenous ligands as well as 
various drugs, many organic dyes and pH indicator substances also bind to 
albumin (Klotz & Ayers, 1953). 
Binding of these ligands has been studied in greater detail at molecular 
level by various workers (Pedersen et al, \911; Brodersen, 1978; Sjoholm & 
Stjema, 1981; Bree et al, 1993; Yong, 1993). These studies have been proved 
usefiil in understanding the functioning of albumin in the transport of these ligands 
under various conditions. Due to the large number of ligands, which bind to 
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albumin, it is difficult to think of the same number of binding sites on albumin 
molecule, and therefore, the binding initially has been considered as a non-specific 
process. Over the past few years, this view has been changed and now it is 
believed that there is small number of distinct binding sites. Based on their binding 
studies, Sjoholm et al. (1979) proposed three different classes of binding sites, 
characterized as warfarin, diazepam and digitoxin binding sites. Although, the 
discrepancies exist about the exact number of discrete binding sites on albumin, 
the general consensus is for two binding sites for small heterocyclic or aromatic 
carboxylic acids, two to three unique long chain fatty acid binding sites separated 
from the binding sites for small anionic compounds and two distinct metal binding 
sites making an overall six dominant binding areas on albumin molecule (Lindup, 
1987). From the three-dimensional structure of albumin, specialized cavities in 
sub-domains IIA and III A have been identified as sites for small heterocyclic and 
aromatic carboxylic acids (He & Carter, 1992). Lately, Peters (1996) suggested 
that there are two major specific drug binding sites on serum albumin. Site-I to 
which ligands such as the bulky heterocyclic anions with the charge situated in a 
central positions of the molecule binds, and site-II were generally, the carboxylic 
acids with an extended conformation and the negative charge binds effectively (He 
& Carter, 1992; Yamasaki etal, 1996). 
The over all distribution, metabolism and efficacy of many drugs can be 
altered based on their affinity to serum albumin (Carter & Ho, 1994). The percent 
binding of tetracycline in human plasma has also been extensively studied using 
ultrafiltration, equilibrium dialysis and spectrophotometric techniques (Green et 
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al, 1976; Zia & Price, 1976). However, the reported data is quite variable, 
primarily due to differences in the sensitivity and specificity of methods used to 
determine the extent of binding (Kunin et al. 1959; Kirby et al, 1962; Bennett et 
al, 1965). Although, high-resolution crystal structures have revealed major 
ligands binding sites on serum albumin (Carter & He, 1992; Yamasaki et al, 
1996; Curry et al, 1999), the exact location of tetracyclines are still obscure and, 
therefore, the binding parameters need to be assessed. 
Free radical-induced protein damage 
Proteins exposed to oxygen radicals exhibit altered primary, secondary and 
tertiary structures, and can undergo spontaneous fragmentation and induced 
proteolytic susceptibility. Similarly, other studies have shown that oxygen radicals 
and other activated oxygen species such as H2O2 can increase protein degradation 
in intact cells and intracellular organelles, as well as in vitro systems (Chin et al., 
1982; Levine, 1983; Davies, 1985; Davies et al, 1987; Davies & Delsignore, 
1987). The active oxygen species also alter cell proteins, making them more 
susceptible to degradation by intracellular proteolytic systems (Davies, 1986; 
Stadman, 1986; Wolff e? al, 1986; Davies, 1987). Free radicals such as -OH and 
possible alkoxy (RO") intermediates of lipid peroxidation have also been reported 
to fragment and crosslink proteins (Schuessler & Schilling, 1984; Wolff et al, 
1986). The sensitivity of proteins to oxygen free radical attack is now well 
established. In the absence of molecular oxygen, 'OH radicals are known to 
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induce crosslinks in proteins, which are often resistant to reduction, such as 
dityrosine (Halliwell & Gutteridge, 1984). Some crosslinking may also occur in 
the presence of oxygen without any significant fragmentation. Protein 
fragmentation by 'OH is a selective process, which generates the fragments of 
defined length (Gutteridge & Wilkins, 1983; Wolff & Dean, 1986). However, the 
number of fragments produced varies from protein to protein. Fragmentation of 
protein in an aqueous solution reportedly increases the number of soluble amino 
groups (Wolff & Dean, 1986), suggesting that cleavage involves peptide bond 
hydrolysis. Proteins are fragmented and modified by H2O2 in the presence of 
transition metals or suitable chelates (Gutteridge & Wilkin, 1983; Wolff & Dean , 
1986). 
There has been much interest in the role of free radicals in human disease 
(Slater, 1984; Clark et al, 1985; Sies, 1985). The Oz*" and H2O2 are known to be 
produced in many biological systems but those are relatively harmless as they 
react with biomolecules at low rates and specific enzymes exist to remove them. 
However, in presence of certain metal ions, the presence of 02'~ and H2O2 can 
lead to the formation of the highly reactive hydroxyl radicals. For this reaction, 
cells usually keep metal ions very firmly bound in unreactive forms (Halliwell & 
Gutteridge, 1986). A major proportion of intracellular copper ions also remains 
bound tightly to serum albumin. 
Earlier studies revealed that oxidative modification of certain proteins could 
render them more susceptible to enzymatic hydrolysis by a number of proteinases 
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(Fligiel et al, 1984; Wolff & Dean, 1986; Davies, 1987). The degradation of 
proteins may occur by a two-step mechanism. Firstly, the modified protein 
becomes more susceptible to proteolytic attack and secondly a protease specific 
for the modified protein catalyses the actual proteolytic degradation (Levine et al, 
1981; Toyo-Oka, 1982; Lev et al, 1994). In many cases, exposure of proteins to 
oxygen radicals, both in vivo and in vitro leads to increased exposure of 
hydrophobic surfaces (Wolff et al, 1986; Davies, 1987), which may lead to 
subsequent aggregation and to increased susceptibility to proteolysis (Davies, 
1987; Stadman, 1992). Conformational changes may also be involved in this 
process (Amado et al, 1984). It has reported that about two radical events per 
molecule of BSA, suffice to cause conformational changes detectable in 
fluorescence spectra, and increase in susceptibility to proteinases (Wolff et al, 
1986). 
DNA: 
DNA-ligand interactions 
DNA as a carrier of genetic information is an important target for drug 
interactions as the bound drugs may interfere with the gene expression, DNA 
replication, cell growth and division. The aromatic ligands interact with DNA 
double helix by intercalation between stacked bases, and binding to minor 
grooves. The intercalators bind by inserting a planar aromatic chromophore 
between adjacent DNA base pairs, whereas groove binders fit into the DNA minor 
groove causing perturbation of the DNA structure (Chaires, 1998). The available 
evidence indicates that the antibiotics such as daunomycin (Pigram et al., 1972; 
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DiMarco et al., 1975), anthracycline analogues viz adriamycin, carminomycin, 
pyrromycin, musettamycin, marcellomycin and aclacinomycin (Zunino et al., 
1972; Pachter et al., 1982) bind to DNA either through intercalation of 
hydroxyquinone portion of drugs and/or by electrostatic interactions. Intercalation 
of hydrophobic chromophore between adjacent DNA base pairs is thought to be 
the predominant mode of anthracycline-DNA interaction and has been extensively 
studied (Pigram et al., 1972; Gabbay et al., 1976). However, the electrostatic 
binding, which is a weaker mode of binding than intercalation, consists of an ionic 
interaction between the amino group on the anthracycline amino sugar and 
phosphates on DNA backbone (Pigram et al., 1972; Zunino et al., 1972; Gabbay et 
al., 1976; Patel & Canuel, 1978). Certain drugs including mitomycin C, cisplatin 
and adriamycin interfere with DNA function by chemically modifying specific 
nucleotides. Indeed, mitomycin C is a well characterized antitumor antibiotic, 
which forms a covalent interaction with DNA after reductive activation. The 
activated antibiotic forms a cross-linking structure between guanine bases on 
adjacent strands of DNA thereby, inhibiting single strand formation. 
The antibiotic anthramycin is an antitumor agent, which binds covalently to 
N-2 of guanine located in the minor groove of DNA. It has a preference of purine-
G-purine sequences with bonding to the middle G. Similarly, cisplatin is a 
transition metal complex cis-diamine-dichloroplatinum and clinically used as 
anticancer drug. The effect of this drug is due to the ability to platinate the N-7 of 
guanine on the major groove site of DNA double helix. This chemical 
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modification crosslinks two adjacent guanines on the same DNA strand interfering 
with mobility of DNA polymerases. 
DNA is a negatively charged polyanion attracting counter ions i.e. 
positively charged Na"^ , Ca^ and Mg"^  ions as well as basic residues of proteins. 
The presence of small counter ion affect drug binding. Since the counter ions 
screen and shield the negative backbone surface, the non-electrolytes as well as 
positively charged ligands interact more strongly with the DNA target. High ionic 
strength, however, reduces noncovalent interaction mediated by hydrogen bonds 
and electrostatic interactions. The interaction of DNA with cations, amino acids 
and nucleotides becomes a matter of interest because of implications in the 
biological functioning of DNA. The binding of various dyes, drugs and antibiotics 
to DNA and chromatin have contributed to an understanding of the structure of 
these macromolecules (Muller & Clothers, 1968; Angerer et ah, 1974; Wartell et 
al, 1975; Lawrence & Daune, 1976; Paoletti et al, 1977) and have suggested 
possible mechanisms of the biological activity of some drugs (Goldberg et al., 
1977). 
Free radical-induced DNA damage 
The chemistry of DNA damage by several ROS/RNS has been well 
characterized in vitro (von Sonntag, 1987; Dizdaroglu, 1993; Termini, 2000; Jung 
& Surh, 2001; Srinivasan et al, 2001). The ROS and reactive nitrogen species 
(RNS) include hydroxyl radical ('OH), singlet oxygen (^62), peroxyl (R02*) and 
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alkoxyl radicals (RO*), ozone (O3), nitrous acid (HNO2) and peroxynitrite 
(ONOO") and its decomposition products. The nitric oxide (NO*) and its by 
products (NO "2, ONOO", N2O3, etc.) result in nitrosation and deamination of 
amino groups on DNA bases leading to point mutations (Arroyo et al, 1992; 
Routledge et al, 1994). However, the 02*" and H2O2 do not react with DNA bases 
at all (Lesko et al, 1980; Brawn & Fridovich, 1981; Rowley & Halliwell, 1983). 
Indeed, much of the toxicity of 02*' and H2O2 in vivo arises by their metal ion-
dependent conversion into highly reactive "OH and/or other powerful oxidants 
(Halliwell & Gutteridge, 1988; Nassi-Calo et al, 1989). Hydroxyl radical 
produces a large number of base and sugar-derived products in DNA, as well as 
DNA-protein cross-links (DPCs) (von Sonntag, 1987; Dizdaroglu, 1986; Teoule, 
1987;01einicke/a/., 1987). 
Reactions of 'OH, eaq" and H atom with DNA bases are characterized by 
addition to the double bonds of these molecules to give adduct radicals of bases. 
The abstraction of the H atom by • OH from the methyl group of thymine also 
reportedly occurs (Hazra & Steenken, 1983; Steenken, 1989). In the presence of 
oxygen, pyrimidine radicals add oxygen to give corresponding peroxyl radicals. 
By contrast, evidence indicates that the majority of purine adduct radicals do not 
react with oxygen (Steenken, 1989; Isildar et al., 1982). Subsequent reactions of 
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base radicals lead to a variety of products from each of the DNA bases (von 
Sonntag, 1987, Dizdaroglu, 1986, Teoule, 1987). 
Hydroxyl radical also reacts with sugar moiety by abstracting an H atom 
leading to sugar radicals (von Sonntag, 1987). Reactions of sugar radicals lead to 
the release of intact bases, alterations of the sugar moiety, and strand breaks (von 
Sonntag, 1987; Dizdaroglu et al., 1977; Beesk et al., 1979). Altered sugars are 
released or remain in the DNA backbone. Some of the altered sugars, which 
remain in the DNA backbone, constitute the so-called alkali-labile sites (Mee & 
Adelstein, 1981, Oleinick et al, 1987, Lesko et al, 1982). 
The primary or the most susceptible target of free radicals in vivo is DNA. 
Both ROS and RNS mediated 'spontaneous' DNA damage contributes to 
tumorigenesis and cancer development. Several ROS/RNS have the potential to 
contribute to cancer development as they can cause structural alterations in DNA 
eg. base pair mutations, rearrangements, deletions, insertions and sequence 
amplification (Zimmerman & Cerutti, 1984; Weitzman et al, 1985). Recently, the 
chronic exposure of hepatocytes to reactive nitrogen species following liver injury 
and inflammation has been reported to causes functional and morphological 
alterations in the liver leading to degenerative liver diseases and hepatocellular 
carcinoma (D'Ambrosio et al, 1997; 2001). 
Chemical-induced lesions in DNA: 
Alkylation 
Compounds that transfer alkyl residues to DNA include the nitrosamines, 
aliphatic epoxides, aflatoxins, lactones, nitrosoureas, mustards, haloalkanes and 
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alkyl triazenes. The action of the alkylating agents on the DNA is complex. These 
are electrophilic in nature and react with jiucleophilic centers, particularly at the 
N-7 position of guanine. Mostly the ring nitrogen atoms and exocyclic oxygen 
atoms are targets for alkylation with the position-7 of guanine being the most 
preferred site (Figure 5). However, the exocyclic amino groups are not effectively 
targeted by the alkylating agents. The order of reactivity of different nucleophilic 
centers is N ' -G»N^-A>N'-A=N^-G=0^-G (Friedberg, 1985). The alkylating 
agents exert a variety of biological effects including mutagenesis and 
carcinogenesis (Lawley & Brookes, 1961; Singer & Kusmievek, 1982). Extensive 
studies have been done on alkylation damage in DNA and its repair (Gibson-
D'Ambrosio et al, 1983; Wani & D'Ambrosio, 1986, 1987; D'Ambrosio et al, 
1990;Wani,e/a/., 1990) 
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Figure 5. Potential alkylation sites on DNA bases (Adapted from 
Dipple, 1995). 
Individual alkylating agents distribute themselves over the target sites as 
summarized in Figure 5. It is suggested that the mutagenic properties of alkylating 
agents have been attributed to their capacities for alkylation at the exocyclic 
oxygen of guanine residues (Loveless, 1969). Also the alkylation at exocyclic 
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oxygens of thymine residues is important in mutagenesis (Singer & Essigmann, 
1991). In general, it seems that alkylating agents that are not particularly ionic in 
nature are localized more in the ring nitrogen atoms, whereas those that have ionic 
character show greater preferences for reaction at the oxygen atoms in DNA 
(Moschel et ai, 1979; Lawley, 1984). Another complexity of alkylation chemistry 
is that the ring nitrogen substituted products are all unstable and thus the 
biological effects can be influenced by chemical transformations secondary to the 
initial DNA alkylation. Examples of such instability are the fairly facile 
depurination and imidazole ring opening of 7-substituted deoxyguanosine residues 
and the depurination of 3- and 7-alkyadeoxyadenosines (Lawley, 1966). It has 
been established that alkylation of purines in DNA leads to their hydrolytic 
separation from the macromolecule at neutral pH indicating the first step in the 
degradation of alkylated DNA. The fission of the glycosyl bond leaves an unstable 
deoxyribose residue that would be expected to hydrolyze by the acid catalyzed 3-
elimination process (Brown & Todd, 1955), resulting in cleavage of the 
macromolecular chain. The formation of cyclic phosphate ester on the other hand 
with the vicinal OH group is also envisaged as leading to chain breakage. Alkaline 
sucrose sedimentation studies also demonstrated the induction of single strand 
breaks plus alkali labile bonds by alkylating agent N-nitrosourea in rat tissues in 
vivo (Su, et a/., 1983) 
Arylamination 
A heterogeneous group of carcinogens including the aromatic amines and 
amides, the aminoazo dyes, the nitroaromatics and the heterocyclic aromatic 
32 
amines found in trace amounts in cooked fish and meats transfer an arylamine 
residue to DNA. The site of substitution on the nucleoside varies substantially and 
forms a pattern that is very different from that displayed by the alkylating agents 
(Figure 6). Clearly, the C-8 atom and the amino groups of the purine nucleosides, 
particularly of deoxyguanosine, are the major targets for the arylaminating agents. 
These sites are unaffected by alkylating agents. Earlier studies have suggested that 
the aromatic amine adducts formed at C-8 of deoxyguanosine arise from a 7-
substituted deoxyguanosine precursor, indicating that a reactivity towards the 7-
position of deoxyguanosine residues may be common to both the alkylating and 
arylaminating agents (Humphreys et al., 1992). An adduct in which the nitrogen 
of an aromatic amine bound to the N-7 position of an 8- methylguanine derivative 
has been characterized. Although, the products of arylamination of DNA are 
reported to be more stable than alkylation products, some C-8 substituted 
deoxyguanosine adducts undergo 8,9-purine ring opening more frequently 
(Kadlubar, 1994). 
i 
sugar y 
Deoxyguanosine Deoxyadenosine 
I 
sugar ^ I 
^ sugar 
Deoxycytidine Thymidine 
Figure 6. Sites of substitution of DNA bases by arylaminating agents (Adapted 
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Aralkylation 
Compounds that transfer an aralkyl group to DNA include the pyrrolizidine 
alkaloids, alkenyl benzenes, the large group of polycyclic aromatic hydrocarbons 
and those nitroaromatics that are activated through the dihydrodiol epoxide 
mechanism. The alkenyl benzenes react with DNA in a way that is not dissimilar 
to the reactions of the arylaminating agents. Thus, 1' -acetoxysafrole react with 
DNA through the formation of adducts at the amino group of deoxyguanosine 
residues and product is also formed at the C-8 position. The enhanced acidic 
ionization of 7-alkyl deoxyguanosine at pH 7.0 compared with the lower extent of 
deoxyguanosine ionization could increase the probability of anomalous base 
pairing between alkylated guanine in DNA and thymine (Lawley & Brookes, 
1961). 
The base modification or loss of alkylated bases from DNA is a potential 
cause of mutagenesis. The base deleted as a result of alkylation could be either 
guanine after its alkylation at N-7, or adenine after its alkylation at N-3. The loss 
of latter occurs more rapidly after alkylation but may be less in over all extent. A 
large number of base deletions from a DNA molecule might be expected to lead 
ultimately to fission of the molecule. It, therefore, seems possible that purine 
deletion would be more likely to be a lethal process than the initial alkylation and 
hence the biological expression of the latter being more likely to be mutagenic. 
CHapter II 
Qenera[ 
Material Q3^ MetHocfs 
[1] MATERIALS 
1.1. Proteins 
Bovine serum albumin (grade V), ovalbumin, cytochrome C, a-
chymotrypsin and superoxide dismutase (SOD) were purchased from Sigma 
Chemical Company, St. Louis, U.S.A. Commercial preparation of BSA was made 
free from dimers and other aggregated forms by passing through Sephadex G-lOO 
(2.5 X 100 cm) column. This preparation was used throughout these studies. 
1.2. DNA 
Calf thymus DNA (sodium sah, average mol.wt. one million), was obtained 
from Sigma Chemical Co., St.Louis, USA. Supercoiled plasmid pBR322 DNA. 
was purchased from Genei, India. 
1.3. Drugs/Ligands 
Tetracycline, chlorotetracycline, oxytetracycline, doxycycline and 
demeclocycline hydrochloride were obtained from Hi-Media, India. Diazepam and 
bilirubin were obtained from Sisco Research Laboratories and Ranbaxy, India, 
respectively. 
1.4. Reagents used in electrophoresis 
Acrylamide and N, N'- methylenebisacrylamide were purchased from Sisco 
Research Laboratories Pvt. Ltd., Mumbai, India. Glycine, dimethyldichlorosilane, 
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coomassie brilliant blue R-250 and sodium dodecylsulfate (SDS) were obtained 
from Sigma Chemical Company, St. Louis, USA. Ammonium persulfate, glycerol, 
glacial acetic acid and methanol were procured from Qualigens Fine Chemicals, 
Mumbai, India. TEMED was the product of Fluka AG, Switzerland. 2-
Mercaptoethanol was purchased from E. Merck, Darmstadt, Germany. 
Bromophenol blue was the product of B.D.H., Poole, England. 
1.5. Reagents used in protein estimation 
2,4,6-trinitrobenzene sulfonic acid (TNBS) was purchased from Pierce, 
U.S.A. 2,4-dinitrophenylhydrazine and acetophenone were purchased from s.d. 
fine chemicals, India. Analytical grade samples of sodium hydrogen carbonate, 
sodium carbonate, sodium potassium tartarate, copper sulfate, sodium molybdate, 
sodium tungstate and hydrochloric acid were obtained from Qualigens Fine 
Chemicals, Mumbai, India. Folin-phenol reagent was prepared according to the 
standard procedure (Folin & Ciocalteu, 1927). Copper reagent was prepared by 
mixing 1 volume of 4% (w/v) sodium potassium tartarate with 100 volume of 4% 
(w/v) sodium carbonate and finally adding 1 volume of 2% (w/v) copper sulphate. 
1.6. Reagents used in agarose gel electrophoresis 
Agarose, ethidium bromide, bromophenol blue were obtained from Sisco 
Research Laboratories Pvt. Ltd. India. Sucrose was procured from Qualigens Fine 
Chemicals, Mumbai, India. Trizma base (Tris [hydroxymethyl] aminomethane) 
was obtained from Sigma Chemical Co., St. Louis, USA. 
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1.7. Metals used 
CuCb, MgCb, CaCl2, NiCl2, ZnCb and FeCls were obtained from 
Qualigens Fine Chemicals, India. 
1.8. Other reagents 
Nitrobluetetrazolium chloride (NBT), dimethyl sulfoxide (DMSO), 
trichloro acetic acid, neocuproine hydrochloride, hydroxyapatite and thiourea were 
purchased from Sisco Research Laboratories, Pvt. Ltd., Mumbai, India. 
Bathocuproine disulfonic acid and salicylate were obtained from Sigma Chemical 
Co., St. Louis, USA. Methanol was procured from Spectrochem Pvt. Ltd. 
Mumbai, India. Mannitol was obtained from Loba Chem., India. Disodium 
hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen 
phosphate, potassium dihydrogen phosphate, triton X-100, diethyl ether, sodium 
azide, sodium benzoate, sodium tungstate, potassium hydroxide and ethylene 
diaminetetra acetic acid (EDTA) were procured from s.d.fme chemical Pvt. Ltd. 
India. Sodium nitrite, potassium iodide and sulfuric acid were purchased from E. 
Merck, Ltd. India. Sodium chloride, sodium hydroxide, potassium dichromate, 
hydrochloric acid, diphenylamine, perchloric acid (70%), formamide, sodium 
acetate and zinc sulfate were obtained from Qualigens Fine Chemicals, Mumbai, 
India. 
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1.9. Miscellaneous 
Millipore filters (pore sizes 0.25 and 0.45 |im) were purchased from 
Millipore Pvt. Ltd., Bangalore, India. Whatman filter papers (No.l) were the 
product of Whatman International Ltd, Maidstone, England. Parafilm 'M' was 
obtained from American Can Company, CT, USA. pH indicator papers were 
obtained from Qualigens Fine Chemicals, Mumbai, India. Aluminium foil was 
obtained from S.R. Foil Ltd. New Delhi, India. Glass double distilled water was 
used throughout these studies. 
[2] METHODS 
2.1. pH measurements 
pH measurements were carried out on an Elico digital pH meter, model LI 610 
using a combined electrode (Type CL-51). The least count of the pH meter was 
0.01 pH unit. The pH meter was routinely calibrated at room temperature with 
standard buffers of pH 4.0, 7.0 and 9.2. 
2.2. Determination of protein concentration 
Protein concentration was determined either spectrophotometrically or by 
the method of Lowry et a/. (1951) using BSA as a standard. 
(a) Spectrophotometric method 
Protein concentration was determined following absorbance measurement 
at 280 nm on a Cecil double beam spectrophotometer, model CE 594, and using 
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the value of specific extinction coefficient (E^ '^ icm) as 6.67 for BSA (Pace et al., 
1995) 
(b) Method ofLowry et al (1951) 
Increasing volumes of stock protein solution (500 fxg/ml) in the range of 
0.1-1.0 ml were taken in different test tubes and the volume in each tube was made 
to 1.0 ml with 60 mM sodium phosphate buffer, pH 7.0. Then, 5.0 ml of freshly 
prepared copper reagent was added to all the tubes and the contents were mixed 
well. After 10 min of incubation at room temperature, 1.0 ml of diluted Folin-
phenol reagent was added and vortexed. The tubes were incubated for 30 min at 
room temperature and the color intensity was read at 700 nm against a reagent 
blank. A calibration curve, thus obtained, between absorbance at 700 nm and 
amount of protein yielded the following straight line equation (Figure 7). 
(Absorbance)7oo nm = 1.4 x 10'^  (protein concentration, |ig/ml) + 0.05 
2.3. Quantitative analysis of free- amino groups in solution 
Calibration curve of glycine was obtained using TNBS reagent according to 
the method of Snyder & Sobocinski (1975). Increasing concentrations of glycine 
solution in the range of 0-750 |iM were taken in different test tubes in a total 
volume of 1.0 ml. To this solution, 1 ml each of 4% NaHCOg and 0.1% TNBS 
were added. The reaction mixture was incubated at 37°C for 2 h. Subsequently, 1 
ml of 10% SDS was added to solubilize the aggregated amino acids. The 
precipitation, if any, was prevented with the addition of 0.5 ml IN HCl. The 
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Figure 7. Calibration curve for the estimation of protein concentration 
by the method of Lowry et al. (1951) using BSA as a standard. 
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absorbance of the solution was read at 335 nm against a reagent blank and plotted 
as a function of glycine concentration (Figure 8). 
2.4. Quantitative analysis of carbonylgroups in solution 
The carbonyl groups were estimated using 2,4-dinitrophenylhydrazine 
reagent following the procedure of Lappin and Clark (1951). Increasing 
concentrations of acetophenone stock solution (10 mM) in the range of 50-500 
|iM were taken in different test tubes in a total volume of 1.0 ml. 1.0 ml of 2,4-
dinitrophenylhydrazine reagent (a saturated solution prepared in carbonyl free 
methanol) and one drop of concentrated hydrochloric acid were added. The tubes 
were loosely stoppered and heated in water bath at 100°C for 5 min. After cooling, 
5.0 ml of the potassium hydroxide solution was added. A rapid color 
transformation from a black solution to characteristic wine red color occurred. A 
reagent blank using 1.0 ml of the carbonyl-free methanol was run simultaneously. 
The absorbance of the solution was read at 480 nm using spectrophotometer CE-
594. A calibration curve (Figure 9) was plotted between the absorbance at 480 nm 
and concentration of acetophenone (carbonyl groups). 
2.5. Quantitative analysis ofDNA in solution 
Spectrophotometric estimation of DNA was carried out according to the 
method of Schneider (1957) by using diphenylamine reagent. 
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Figure 8. Calibration curve for the estimation of free amino acid 
(glycine) by the method of Snyder and Sobocinski (1975). 
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Figure 9. Calibration curve for the estimation of carbonyl groups 
by the method of Lappin and Clark (1951) 
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(a) Diphenylamine reagent 
1.0 gram of diphenylamine was accurately weighed and dissolved in 100 ml 
of glacial acetic acid. To this 2.75 ml of concentrated sulfuric acid was added and 
mixed thoroughly. The diphenylamine reagent was prepared fresh at the time of 
experiment. 
(b) Assay procedure 
Varying amounts of stock DNA (500 j^g/ml) in a constant volume of 1.0 ml 
were mixed with 2.0 ml of diphenylamine reagent and heated for 20 min in a 
boiling water bath. The absorbance of the blue color developed was read at 600 
nm and a calibration curve was plotted (Figure 10). 
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Figure 10. Calibration curve for the estimation of calf thymus DNA by 
the method of Schneider (1957). 
CHapter III 
Interaction of retracycfines 
with Serum JtCBumin 
1. Introduction 
Tetracycline (TC) and its derivatives, including 5a-hydroxytetracycline 
(OTC), 6a-deoxy-5a-hydroxytetracycline (DOTC), 6-demethyl-7-
chlorotetracycline (DMTC), and 7-chlorotetracycline (CTC) are knov^ n for their 
photoreactive properties (Orentreich et ah, 1961; Cullen et al.,1966; Blank et al., 
1968; Frost et al., 1972; Hasan et ai, 1984). The photosensitivity and 
phototoxicity (Frost et ai, 1971; Epstein et al., 1976) of these pharmacological 
drugs are manifested as skin lesions (Cullen et al.,1966), onycholysis (Orentreich 
et ai, 1961), papular eruptions (Frost et al., 1971) and formation of multinucleated 
giant cells (Zuehlke, 1973). These drugs after ingestion are solubilized in guts and 
transported to the target sites through blood, bound to serum proteins. The serum 
albumin, one of the most abundant carrier proteins, plays an important role in the 
transport and deposition of variety of endogenous and exogenous ligands in blood 
(Sudlow et al., 1975; Jusko & Gretch, 1976; Muller & Wollert, 1979; Vallner, 
1977; Fehske et al., 1981; Kragh-Hansen, 1981; He & Carter, 1992; Carter & Ho, 
1994). Indeed, there are two major specific drug binding sites (site-I and -II) on 
serum albumin (Sudlow et al., 1975; 1976). Albeit, the high-resolution crystal 
structures revealed the major ligand binding sites on serum albumin (He & Carter, 
1992; Yamasaki et al., 1996; Curry et al., 1999), the exact location of many 
ligands is still obscure. Since the overall distribution (Kunnin, 1965; Merrikin, 
1983), metaboHsm and efficacy (Tompsett et al., 1947; Shyu et al., 1988) of many 
drugs in the body are correlated with their affinities towards serum albumin, the 
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investigation of pharmaceuticals with respect to albumin-drug binding is 
imperative and of fundamental importance. 
Several pharmaceutical drugs including certain antibiotics viz. penicillin, 
cefoxitin, cefazolin, cephalosporins have been reported to bind reversibly with 
serum albumin to different extents, depending on their side chain functional 
groups (Keen, 1966; Bakker-Woudenberg et al., 1985; Nouda et al., 1986; Tawara 
et al., 1992). Also, the percent binding of tetracycline in human plasma has been 
extensively studied using ultrafiltration, equilibrium dialysis and 
spectrophotometric techniques (Bennett et al., 1965; Green et al., 1976; Zia & 
Price, 1976). However, the earlier reported data are inconsistent primarily due to 
differences in the sensitivity and specificity of methods used to determine the 
extent of binding (Green et al., 1976; Bakker-Woudenberg et al., 1985; Tawara et 
al., 1992). In addition, there are contradictory reports in the literature regarding the 
role of some divalent metal ions in the binding of tetracyclines with biological 
macromolecules (Kohn, 1961; Popov et al., 1972; Zia & Price, 1976). 
The quantitative binding of tetracycline and its derivatives with serum 
albumin and the resultant structural alterations in the carrier protein are rarely 
reported. This prompted us to investigate the (i) extent and nature of interactions 
of tetracyclines with serum albumin (ii) binding constant (Ka) and capacity (n) of 
serum albumin for tetracyclines, (iii) influence of metal ions on drug-albumin 
interactions, and (iv) drug-induced conformational changes in protein, using the 
sensitive techniques such as fluorescence spectroscopy and circular dichroism. 
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Indeed, a better understanding of the important binding parameters influencing the 
transport, metabolism, eUmination, bioavailabiUty and toxicity of these drugs in 
the body is needed. In this regard, the knowledge of the binding characteristics of 
serum albumin for tetracyclines in the presence and/or absence of metal ions will 
provide useful evidence for establishing a predictable correlation between the drug 
distribution, stability, pharmacokinetic and phototoxic behavior. 
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2. Materials and Methods 
2.1. Fluorescence measurements 
Fluorescence measurements were made on a Shimadzu spectrofluorometer, 
(model RF-540) equipped with a data recorder DR-3. The fluorescence spectra 
were measured at a protein concentration of 6.0 )LIM with a 1 cm path length cell. 
Excitation and emission slits were set at 10 nm each. The spectra were recorded in 
300-400 nm range and the excitation wavelength was set at 280 nm. All the stock 
solutions were filtered through 0.45)im Millipore filters prior to mixing, to 
minimize the inner filter effect (Chignell, 1972). 
2.2. Binding data analysis 
Binding affinities of tetracyclines with serum albumin were determined 
according to the method of Levine (1977). In brief, to a fixed concentration (6.0 
)nM) of protein solution the varying amounts of tetracyclines were added to obtain 
the desired molar ratios. The final volume in each case was adjusted to 5 ml with 
10 mM Tris-HCl buffer, pH 8.0. The fluorescence intensity values at emission 
maxima (340 nm) were used for calculating the relative fluorescence, considering 
the fluorescence intensity of control untreated protein as 100. The least square 
analysis of the initial linear points of relative fluorescence versus drug to albumin 
molar ratio was used to determine the maximal quench, m (slope of the plot) from 
the following equation [F = FQ -mR]; where, F is the fluorescence intensity at 
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drug to albumin ratio (R) and FQ is the fluorescence intensity of protein at zero 
concentration of drug. Using the data points exhibiting deviation from the straight-
line behavior, the fractional quench, Q, was determined at each drug/albumin 
molar ratio (R). For an observed fluorescence intensity F, the value of Q was 
obtained from the equation [Q = FQ - F/maximal quench (m)]. Fractional quench 
(Q), is linearly related to drug binding: [Drug-Albumin]/[Albumin]T = Q, where, 
the [Albuminjx represents the total albumin concentration. Binding affinity (Kg) 
and binding capacity (n) were determined from the slope and intercept on X-axis 
of the straight line on the Scatchard plot Q vs Q /(R-Q)[Albuminjx (Levine, 1977). 
For determining the effect of metal ions on tetracyclines-BSA binding, BSA 
(6p,M) was separately treated with tetracyclines (10 ^M) in presence of metal ions 
(20 )iM). Fluorescence intensity of BSA alone was 80.4, measured at the 
excitation and emission wavelengths of 280 nm and 340 nm, respectively. 
2.3. Determination of site-specificity of tetracycline binding on albumin using 
marker ligands 
The putative binding sites of tetracycline and its derivative on albumin 
molecule have been identified using the marker ligands such as bilirubin and 
diazepam specific for site I and site II, respectively. In this study, tetracyclines 
were used as fluorescence probes and the changes in fluorescence intensity of 
protein bound TC were monitored at 525 nm after excitation at 390 nm upon 
addition of equimolar amounts of marker ligands. The percent reduction in 
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fluorescence intensity upon marker ligand binding was calculated considering the 
fluorescence intensity of TC-albumin complex as 100 percent and percent binding 
of TC at specific sites on protein. 
2.4. Circular dichroism (CD) measurements 
The CD measurements were carried out on a Jasco spectropolarimeter, 
model J-720. The instrument was calibrated with d-10-camphorsulphonic acid. 
All the CD measurements were performed at 25°C with a thermostatically 
controlled cell holder attached to a NESLAB RTE -110 water bath (NESLAB 
Instruments, Inc. USA) with an accuracy of ± 0.1 °C. Spectra were collected at a 
scan speed of 20 nm per min with a response time of 1 sec. Each spectrum was the 
average of 4 scans. Far-UV CD spectra (200-250 nm) were taken at a protein 
concentration of 2.4 ^M with a 1mm path length cell. The protein samples for CD 
measurements were filtered through a Millipore filter (0.45|iM) to remove any 
suspended material. The results were expressed as mean residue ellipticity (MRE) 
in deg.cm^.dmol'', which is defined as [MRE = 9 obs (mdeg)/10 x n x 1 x Cp]. The 
Gobs represents the ellipticity in millidegree, n is the number of amino acid residues 
(583), 1 is the path length of the cell in cm and Cp is the mole fraction. The a-
helical content of BSA was calculated from the MRE value at 222 nm using the 
equation % helix = [(MRE222 -2340)/30300] x 100 as described by Chen et al. 
(1972). 
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3. Results 
3.1. Quantitative binding of tetracyclines with serum albumin 
The interactions of the tetracychnes with albumin were analyzed by 
measuring the changes in the intrinsic fluorescence of serum albumin at different 
drug/protein molar ratios. Figures 11-15 show the fluorescence emission spectra of 
albumin-drug complex at 300-400 nm in the range of 0-4 protein-drug molar 
ratios. The relative fluorescence intensities of BSA at varying drug/protein molar 
ratios were determined from the spectra of tetracyclines and plotted as a function 
of [drug]/[albumin] molar ratio. The binding isotherms and the corresponding 
Scatchard plots of Q/[drug] x 10"^  vs Q for tetracycline and its derivatives are 
shown in Figures 16 and 17 (A to D). The binding isotherms exhibit the drug 
concentration dependent quenching of intrinsic fluorescence of protein. The total 
percent quench for TC, OTC, DOTC, DMTC and CTC, were determined to be 
61.2%, 54.0%, 55.5%, 66.7% and 69.5 % respectively at the highest molar ratios. 
The slope and intercept of the straight line obtained on the plot Q/[drug] x 10"^  vs 
Q provided the binding constant (Kg) and binding capacity (n) of albumin for 
different tetracyclines. The estimated comparative binding parameters of 
tetracycline and its derivatives are shown in Table 4. Amongst the tetracyclines, 
TC was found exhibiting strongest binding affinity (Ka = 4.6 x 10^  litre/mole) 
followed by the Ka values of 3.4 x 10^ 2.1 x 10^ 1.3 x 10^  and 0.95 x 10^  
litre/mole for derivatives DOTC, OTC, DMTC and CTC, respectively. Similarly, 
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Figure 11. Emission spectra of BSA in the absence (uppermost 
curve) and presence of increasing amounts of TC. The spectra 
were obtained in 0.01 M Tris-HCl buffer, pH 8.0,7=0.15 at 28°C. 
The molar ratios of TC to BSA were: (top to bottom) 0.0, 0.28, 
0.56, 0.83, 1.1, 1.4, 1.7, 1.9, 2.2, 2.5, 2.8, 3.0, 3.3, 3.6, 3.9, 4.1 
respectively. 
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Figure 12. Emission spectra of BSA in the absence (uppermost 
curve) and presence of increasing amounts of CTC. The spectra 
were obtained in 0.01 M Tris-HCl buffer, pH 8.0,7=0.15 at 28°C. 
The molar ratios of CTC to BSA were: (top to bottom) 0.0, 0.2, 
0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 
3.4, 3.6, 3.8,4.0 respectively. 
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Figure 13. Emission spectra of BSA in the absence (uppermost 
curve) and presence of increasing amounts of OTC. The spectra 
were obtained in 0.01 M Tris-HCl buffer, pH 8.0,7=0.15 at 28°C. 
The molar ratios of OTC to BSA were: (top to bottom) 0.0, 0.1, 
0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 
1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0 respectively. 
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Figure 14. Emission spectra of BSA in the absence (uppermost 
curve) and presence of increasing amounts of DOTC. The spectra 
were obtained in 0.01 M Tris-HCl buffer, pH 8.0,7-0.15 at 28°C. 
The molar ratios of DOTC to BSA were (top to bottom) 0.0, 0.1, 
0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 
1.7, 1.8, 1.9, 2.0 respectively. 
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Figure 15. Emission spectra of BSA in the absence (uppermost 
curve) and presence of increasing amounts of DMTC. The 
spectra were obtained in 0.01 M Tris-HCl buffer, pH 8.0, 7=0.15 
at 28°C. The molar ratios of DMTC to BSA were (top to bottom) 
0 0, 0.2, 0.4, 0 6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2 4, 2.6, 2.8, 
3.0, 3.2, 3.4, 3.6, 3.8,4.0 respectively 
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Figure 16. Tetracycline - albumin binding isotherm showing relationship 
between relative fluorescence and molar ratio in the range ofO to 4. The 
inset shows the Scatchard plot for the binding of tetracycline to BSA. 
The values for Q/[TC] x 10"^ and Q were obtained using the mathematical 
derivation as described in the methods and plotted according to the method 
ofLevine(1977). 
Drug/BSA Molar Ratio 
Figure 17. The binding isotherms and Scatchard analysis of the fluorescence data. The 
curves A-D shows the relationship between the fluorescence and drug-albumin molar 
ratios. The inset shows the Scatchard plot for binding of the corresponding derivatives 
with BSA. The values for Q/[OTC], Q/[DOTC], Q/[CTC], Q/[DMTC] x 10 -^  versus Q 
were obtained using the mathematical derivation as discussed in the methods and plotted 
according to the method of Levine (1977). The spectra represents (A) OTC; (B) DOTC; 
(C) CTC; (D) DMTC. 
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Table 4 
Comparative binding parameters of tetracyclines-albumin interaction 
Drugs Binding constant (Ka) Binding capacity AG* 
X10^  (litre/mole) (n) (Kcal/mole) 
TC 4.6 
OTC 2.1 
DOTC 3.4 
DMTC 1.3 
CTC 0.95 
*Calculated from K, values at 25^C. 
3.6 
2.1 
1.3 
3.4 
2.9 
-9.05 
-8.84 
-8.83 
-8.42 
-7.99 
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the binding capacity (n) values of albumin for TC, DOTC, OTC, DMTC and CTC 
were determined to be 3.6, 1.3, 2.1, 3.4 and 2.9, respectively. The differential 
binding affinity of albumin with tetracycline and its derivatives was determined to 
be in the order as TODOTC >OTC >DMTC >CTC. 
3.2. Site-specificity of tetracyclines-albumin binding 
The competitive binding of marker ligands specific for site-I (bilirubin) and 
site-II (diazepam) with albumin-tetracycline complex demonstrated the site 
specificity of tetracycline binding on albumin molecule. The fluorescence intensity 
of tetracycline-albumin complex at 525 nm reduced significantly with the addition 
of equimolar amounts of bilirubin. On the contrary, equimolar amount of 
diazepam showed negligible quenching effect (Table 5). 
3.3. Effect of divalent metal ions on the binding of tetracyclines with albumin 
Figure 18 shows the representative fluorescence spectra of albumin treated 
with 10 jiM TC in presence of 20 )iM Cu (II) ions. The results exhibit significant 
Cu (Il)-mediated decrease in the intrinsic fluorescence of protein at a constant 
concentration of TC. The percent quench was determined to be significantly 
higher with the TC plus 20 |iM Cu (II) complex compared with TC alone. The 
effect of other metal ions such as Zn (II), Ni (II) and Fe (II) in combination with 
other tetracyclines on the intrinsic fluorescence of BSA has also been studied. The 
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Table 5 
Effect of marker ligands on the binding of tetracyclines to BSA 
Drug/BSA 
Molar ratio 
(1:1) 
* Fluorescence quenching with marker ligands (%) 
Bilirubin (site 
14.3 
21.0 
24.4 
75.5 
28.1 
-I) Diazepam (site-II) 
6.0 
3.0 
0.0 
5.0 
0.0 
TC 
CTC 
OTC 
DOTC 
DMTC 
*Calculated from the fluorescence intensity of BSA-TC complex in presence of the marker 
ligands considering fluorescence intensity of TC-BSA complex as 100. 
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Figure 18, Effect of Cu (II) ions on tetracyline-albumin binding. 
The spectra top to bottom represents (1) BSA alone; (2) BSA + 
20 i^M Cu (II); (3) BSA + 10 fiM TC; (4) BSA + 20 nM Cu (II) + 
10 ^M TC. Excitation wavelength was 280 nm. 
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data shown in Table 6 clearly indicate the enhanced binding of tetracycline 
derivatives with albumin in the presence of metal ions. 
3.4. Induced conformational change in serum albumin with tetracyclines 
Figure 19 shows the far-UV CD spectra of BSA in the range of 200-250 nm 
at varying concentrations (0.0-1.0 mM) of tetracycline in the presence of 100 |iM 
Cu (II) ions. The typical curve of BSA in its native state with two peaks at 208 and 
222 nm, exhibited a drug concentration dependent change in the ellipticity value. 
The changes in mean residue ellipticity (MRE222) values as a function of 
concentration of the tetracyclines are shown in Figure 20. The decrease in MRE222 
for the tetracyclines was determined to be in the order as 
TC>DOTC>OTC>DMTC>CTC. The significant reductions in the MRE reflect the 
alterations in protein helicity. The percent changes in the a-helical content of the 
protein, estimated at a fixed (1.0 mM) concentration of each of the tetracycline 
derivatives are shown in Table 7. The loss in protein helicity was determined to be 
25% with tetracycline and 23.6, 21.7, 19.2 and 18.1% with the derivatives DOTC, 
OTC, DMTC and CTC, respectively, vis-a-vis 60 % a -helical content in native 
untreated BSA. 
Table 6 
Effect of certain metal ions on tetracyclines-BSA binding 
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Metals 
Control 
Cu^ ^ 
Ni'" 
Zn'^ 
V^ 
TC 
35.5 
78.2 
49.9 
44.0 
61.4 
CTC 
34.7 
85.6 
84.0 
49.9 
76.8 
Percent fluorescence quenching 
DOTC 
44.7 
82.0 
44.7 
54.7 
61.4 
OTC 
35.5 
75.7 
45.7 
43.5 
60.6 
DMTC 
28.0 
76.9 
57.2 
45.8 
65.4 
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Figure 19. Representative CD spectra of tetracycline-albumin complex. The 
spectra of BSA (2.4 nM) in Tris-HCl buffer, pH 7.4 in the absence and presence 
of varying concentrations (0.0 to 1.0 mM) of tetracycline. The spectra represents 
(1) native BSA, BSA treated with, (2) 0.2 mM TC, (3) 0.4 mM TC, (4) 0.8 mM 
TC, (5) 1.0 mM TC in the presence of 100 nM Cu (II) ions. 
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Figure 20. Comparative mean residual ellipticity (MRE222) values 
of BSA treated with tetracycline and its derivatives. MRE values were 
obtained and plotted as function of tetracyclines concentrations in the 
range of 0.0 -1.0 mM in the presence of 0.1 mM Cu (II) ions. The 
curves represent the BSA complexes with ( -0- ) TC, (—•-) DOTC, 
(_o_) OTC, ( -» - ) DMTC, {-^ CTC. 
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Table 7 
Change in relative a-helicity of BSA upon interaction with tetracyclines in 
presence of 100 jiiM Cu ((II) ions 
Drugs 
(ImM) 
Native BSA 
BSA + TC 
BSA + DOTC 
BSA + OTC 
BSA + DMTC 
BSA + CTC 
(d( 
MRE222 
3g.cm .^dmor') 
20500 
15900 
16200 
16550 
17000 
17200 
% a - helix 
59.90 
44.75 
45.74 
46.89 
48.38 
49.04 
% Perturbation 
25.3 
23.7 
21.8 
19.3 
18.2 
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4. Discussion 
The present study provides the information related to the (i) comparative 
binding of cHnically important tetracycHnes with BSA, (ii) role of divalent metal 
ions in TC-BSA interactions and (iii) ensuing conformational changes in protein 
upon interaction with tetracyclines, based on fluorescence and CD measurements. 
The fluorescence data revealed that the differential binding affinity of BSA for 
different tetracyclines varies in the order as TC>DOTC>OTC>DMTC>CTC. The 
binding isotherms suggested about one to four high affinity binding sites for 
tetracycline and its derivative on albumin molecule, while the remaining sites 
exhibit non specific binding. Due to higher number of low affinity sites, the 
binding of tetracycline derivatives on albumin molecule appears to be non-
saturable. The higher Kg values also suggested strong interaction between 
tetracycline derivatives and albumin, yielding negative AG value. Furthermore, no 
change in the binding affinity with increasing ionic strength clearly suggests the 
major involvement of the hydrophobic forces. This is consistent with the earlier 
data suggesting the role of hydrophobic interaction in TC-BSA binding (Urien et 
al., 1994). However, the role of electrostatic interacfion can not be ignored, as at 
neutral pH, tetracycline acts as a zwitterion. Thus being an ionizable ligand, 
binding of tetracycline to albumin may involve both the hydrophobic and 
electrostatic interactions. Competitive binding data of marker ligands specific for 
site-I and site-II to albumin-tetracyclines suggests that tetracyclines most likely 
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bind to the hydrophobic pockets at or near the site I within sub domain IIA of 
albumin molecule. 
The interaction of BSA with tetracyclines augments with the addition of 
transition metal ions such as Cu (II), Fe (II), Ni (II) and Zn (II) ions. Presumably, 
the metal ions provide the additional binding sites on albumin surface. These 
results corroborate with the earlier data on the metal ion complexation with BSA 
(Kohn, 1961; Kragh-Hansen et ai, 1994). Indeed, the residues at the N-terminus 
particularly histidine-3, cysteine-34 and tryptophan-213 in domain II of bovine 
serum albumin are known to plays a critical role in metal binding (Peters & 
Blumenstock, 1967). It is well known that the N-terminal region of albumin 
possesses high affinity sites for both the Cu (II) and Ni (II) ions. The binding of 
tetracycline with serum albumin has been reported to occur in the presence of zinc 
ions (Kohn, 1961). On the contrary, our studies revealed higher binding of 
tetracyclines on BSA molecule in presence of Cu (II) rather than Zn (II) ions. This 
could be possibly due to simultaneous reactions of Cu (II) with oxygen atoms 
bound at C-3 of amide group and/or at C-10 and C-11 positions of the 
tetracyclines (Buschfort & Witte, 1994). Thus, the higher quenching effect of 
tetracycline-Cu (II) complex on the intrinsic fluorescence of albumin confirms the 
role of Cu (II) in promoting the tetracycline complexation with albumin through 
metal ion bridge formation. Our circular dichroic data also revealed that the 
tetracyclines at higher concentrations in combination of Cu (II) ions induce 
changes in protein ellipticity. 
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There are evidence that the binding of small ligands to serum albumin may 
induce some conformational changes (Jusko & Gretch, 1976; Sudlow et al, 1976). 
The observed change in free energy also supports the structural alterations in the 
albumin molecule upon binding with the tetracyclines in the increasing order as 
TC>DOTC>OTC>DMTC>CTC. Presumably, such conformational changes may 
occur mainly on a site other than the used ligand-binding sites, so that the optical 
properties and the affinity of different sites can be affected. 
In conclusion, the higher binding affinity of tetracycline and its derivatives 
with serum albumin may enhance the stability and potency of these drugs in the 
body. However, the excessive drug binding in presence of metal ions induces 
conformational changes in globular structure of the serum protein. Thus, the 
formation of tetracyclines-Cu (II) complex may evoke potential risk of 
macromolecular damage under physiological conditions. 
chapter IV 
TetracycCines-incfucecf 
damage in Serum M6umm 
1. Introduction 
Tetracycline undergoes oxidative degradation upon photoexcitation and yields 
metastable quinone derivatives (Davies et al., 1979, Moore et ai, 1983). These 
photoinduced products evoke the biological responses manifested as tingling, 
burning sensation (Frank et al., 1971), onycholysis (Orentreich et al., 1961, Frank 
et al., 1971) and papular eruptions (Frost et al., 1971). Upon photosensitization, 
tetracycline looses a dimethylamino group (Moore et al., 1983), and eventually 
triggers the production of free radicals (Davies et al., 1979, Green & Hill, 1984). 
The tetracycline-induced reactive species have been reported to inhibit fibroblast 
growth (Bjellerup et ai, 1985), damage the monocytes (Hasan et al., 1984) and 
inactivates plant and animal viruses (Murphy, 1975, Novo & Esparza, 1979). This 
antibiotic is known to affect DNA synthesis in prokaryotic cells upon interaction 
with the cell membrane (Pato, 1977). It also forms photo-adducts with ribosomal 
proteins (Goldman et al., 1983) and induces single strand breaks in bacteriophage 
(p X 174 DNA (Piette et al., 1986). Other intracellular targets susceptible to 
tetracycline-induced damage, in higher organisms, are erythrocytes (Nilsson et al., 
1975), ribosomes (Rebout et al., 1982, Goldman et al., 1983) and macromolecules 
in cartilage (Monboisse et al., 1983, Dean et al. 1984) and synovial fluid 
(McCord, 1974, Shasby et al, 1985). In the presence of divalent cations, 
tetracycline binds non-covalently to both DNA and serum albumin (Kohn, 1961, 
Khan et al., 1998). The interaction of tetracycline with albumin has also been 
reported to alter the protein helicity as evident from significant changes in the 
mean residue ellipticity of albumin (Khan et al., 1998). 
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Although, the tetracycline-induced free radical production has been 
demonstrated (Anson et al., 1987, Martin et al., 1987), the quantitative data 
exhibiting dose dependence, and the nature and extent of tetracycline-induced 
damage to proteins is still obscure. This prompted us to investigate the 
tetracycline-induced protein damage and to test the hypothesis that the Cu (II) ions 
promote cellular protein degradation due to increased 'OH generation during 
tetracycline photoexcitation. The reactive oxygen species production and 
consequent fragmentation of serum albumin are envisaged as manifestations of 
tetracycline toxicity. 
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2. Materials and Methods 
2.1. Photoexcitation of tetracyclines 
The photoexcitation of tetracycUnes was carried out by exposure to white 
Hght (20WW) emitted from a PhiUps fluorescence lamp with PAR TLD tubes. 
All samples were exposed to luminous radiations in borosilicate glass flasks. The 
light intensity was measured with a PMA 2100 radiometer (Solar light Co. Inc, 
Philadelphia). The protein concentration was determined by the method of Lowry 
etal.{\95\). 
2.2. Quantitation of superoxide anion (O2') andhydroxyl (OH) radicals in 
vitro 
Superoxide anions were estimated by NBT reduction assay according to the 
method of Nakayama, et al. (1983). In brief, the typical reaction mixture 
containing 150 mM potassium phosphate buffer, pH 7.8, 50 )iM NBT, 100 |j,M 
EDTA, 0.06% Triton X-100 was mixed with varying concentrations (0 -300 i^ M) 
of tetracycline. The tubes containing the reaction mixture were exposed to white 
light for specified time periods. The absorbance of the blue color developed was 
read at 560 nm using Shimadzu-4001 UV-Vis spectrophotometer and plotted as a 
function of tetracycline concentration and time of photo-excitation. The hydroxyl 
radicals were estimated according to the method of Richmond et al. (1981) using 
salicylate (2-hydroxybenzoate) as a detector molecule. The reaction mixture 
contains the following reagents at the indicated concentrations i.e 2 mM salicylate, 
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100 ^M EDTA, 100 i^M Cu (II) and 150 mM potassium phosphate buffer, pH 8.0. 
The reaction was started with the addition of tetracycline in concentration range of 
0 - 500 ^M and the tubes were exposed to white light for 2 h at 37°C. The reaction 
was stopped with the addition of 11.5 M HCl, and 0.85 mM NaCl, followed by 4 
ml of chilled diethyl ether. The contents were mixed by vortexing and the upper 
layer of ether was separated and evaporated to dryness in a water bath. The tubes 
were cooled and the residue dissolved in cold distilled water. Then, 0.5 ml of 10% 
TCA, 1 ml of 10 % w/v sodium tungstate in water, 0.7 ml of 0.5% w/v sodium 
nitrite were added to each tube. The tubes were allowed to stand for 5 min, and 0.5 
M KOH was added to adjust the pH of the mixture to pH 7.2. The absorbance was 
read at 510 nm and plotted as a function of tetracycline concentration. The 
quenching effects of free radical scavengers were studied by adding 10 mM each 
of the mannitol, ethanol, DMSO and SOD (150 unit), under identical conditions 
with parallel controls. 
2.3. Tetracycline-induced fragmentation of serum albumin 
Fragmentation of protein was assessed by measuring the released TCA 
soluble amino groups with TNBS reagent according to the method of Snyder and 
Sobocinski (1975). A typical reaction mixture containing serum albumin (50 |j.M), 
varying concentrations of TC (0-1.0 mM) and Cu (II) (100 p.M) was exposed to 
white light for 2 h at 37°C. Similarly, the treatments of BSA with tetracycline 
derivatives were performed under identical conditions. The reaction was stopped 
with the addition of 100 i^M EDTA followed by precipitation with 5% (w/v) TCA. 
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The supernatant was obtained after centrifugation at 2500 rpm for 30 min and the 
acid soluble amino groups were quantitated using the calibration curve of glycine. 
The absorbance was read at 335 nm and plotted as a function of tetracycline 
concentration and time of exposure to white light. Inhibition of protein 
fragmentation was also monitored in presence of 10 mM mannitol and 150 units of 
SOD, as hydroxyl radical and superoxide anion scavengers, respectively. The 
carbonyl groups released from treated BSA were estimated using 2,4-
dinitrophenylhydrazine reagent following the procedure of Lappin and Clark 
(1951). 
2.4. SDS-Polyacrylamide gel electrophoresis 
SDS-polyacrylamide electrophoresis of untreated and tetracycline-Cu (II) 
treated serum albumin was carried out on 10% (w/v) gel, according to the method 
of Laemmli (1970). In brief, the albumin treated with increasing concentrations 
(0.5 to 2 mM) of TC and 100 ^M Cu (II) was photoexcited for 2 h at 37°C. The 
aliquots (24 (ig each) of untreated control and treated protein were loaded on the 
gel and run at 3 mA per well for 3 h. The gel was stained with coomassie brilliant 
blue R-250 (0.25 % w/v) and destained with 5% methanol and 7.5 % glacial acetic 
acid at room temperature. 
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3. Results 
3.1. Quantitative assessment oftetracycline-induced superoxide (O2'') anion 
production 
Figure 21 shows a linear dose dependent increase in the absorbance of blue 
colored formazan products formed as a result of tetracycline photoexcitation in the 
concentration range of 0 - 300 \iM. The absolute amounts of 02'' anions shown in 
Figure 21 (inset) were estimated based on the absorbance data and the molar 
extinction coefficient of the nitroblue formazan (e 15,000) produced upon 
nitroblue tetrazolium reduction. The tetracycline-induced superoxide anion 
production appeared to be a time dependent process. A pronounced increase in 
absorbance at 560 nm was noticed at a fixed (50 |uM) concentration of tetracycline 
with increasing photoexcitation time between 0 - 60 min (Figure 22). The increase 
in absorbance of the formazan products was almost linear up to 20 min of 
irradiation. The curve slopes off and plateaus at the higher exposure times. The 
absolute amounts of 02"' generated as a function of photoexcitation time are 
shown in Figure 22 (inset). The addition of SOD (150 U), as a free radical 
quencher during tetracycline photoexcitation substantially reduces the superoxide 
anion production. Parallel reaction carried out in dark does not elicit any 
superoxide production as evident from negligible change in the absorbance at 560 
nm. The comparative analysis indicates the differential production of ROS with 
the photosensitized tetracycline derivatives with different functional groups in the 
order as DOTO T O OTC>DMTC> CTC (Table 8). 
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Figure 21. Photoexcited tetracycline-induced production of O2' anions. TC 
at an increasing concentration range of 0-300 jiM was photoexcited in 
presence of NBT. The absorbance of the blue colored formazan product was 
read at 560 nm and plotted as a function of TC concentration. The absolute 
amounts of O2' anions produced are shown in the inset. The data plotted as 
( - • - ) untreated control, (-•-) TC (in dark), (-A-) TC (in white light) are 
the mean ± S.D. of two independent experiments done in duplicate. 
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Figure 22. Effect of photoexcitation time on Oa" anions generation. 
Tetracycline at a fixed concentration of 50 nM was photoexcited for 60 min 
in absence (-A-) and presence of SOD (-•-). At regular time intervals of 
5,10, 20, 30,40, 50 and 60 min, the absorbance was monitored at 560 nm and 
plotted as a fiinction of time. The inset shows the values of the absolute 
amount of O:"" anions. Each data point represents the mean + S.D. of two 
independent experiments done in duplicate 
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Table 8 
Production of reactive oxygen species and acid soluble amino groups 
upon tetracyclines-Cu (II) photosensitization 
Drugs 
(100 ^M) 
TC 
CTC 
DOTC 
DMTC 
OTC 
ROS production 
02*' anions 'OH radicals 
(|iM formazan) (nmoles *0H salicylate) 
202 ± 10.6 
112± 2.8 
219± 4.2 
118± 1.4 
147 ±11.3 
64.9 ± 6.2 
35.9 ±1.7 
75.6 ±6.4 
41.5 ±3.5 
49.0 ±2.2 
Protein damage 
Acid soluble amino groups 
(^M) 
87.5 ±1.4 
40.4 ±1.5 
93.3 ±9.7 
46.3 ±2.5 
52.0 ±1.7 
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3.2. Dose-dependent production of 'OH radicals with photosensitized 
tetracycline-Cu (II) 
A linear increase in the hydroxylated salicylate products, as an indicator of 
•OH production was observed upon reaction of 2-hydroxybenzoate with 
photoexcited tetracycline. Figure 23 clearly shows the concentration dependent 
increase in absorbance at 510 nm in the concentration range of 0-500 \\M 
tetracycline during 2 h of photoexcitation at 37°C. The absolute amounts of 
salicylated products formed under specified conditions are shown in the inset. The 
data indicate that the presence of 100 jiM Cu (II) ions during photoexcitation of 
tetracycline resulted in substantial increase in the salicylated product formation. At 
the highest concentration (500 (xM) of tetracycline about 2-fold increase in the 
production of 'OH radicals was observed. The production of "OH radicals was 
validated by measuring the formation of salicylated products in presence of 
various free radical quenchers. In presence of SOD (150 U), almost negligible 
inhibition of salicylated product formation was noticed. However, approximately 
43, 32 and 16% inhibition of salicylated product formation was noticed in 
presence of 10 mM hydroxyl radical quenchers viz. mannitol, ethanol and DMSO 
(Table 9). 
3.3. Tetracycline-Cu (II) induced fragmentation of serum albumin 
Figure 24 shows the tetracycline-induced degradation pattern of serum 
albumin on a SDS-polyacrylamide gel. A significant amount of tetracycline 
100 200 300 400 500 
Tetracycline concentration {[ifA) 
Figure 23. Production of hydroxylated salicylate products with photoexcited 
tetracycline. The absorbance of salicylated products were measured at 510 nm and 
plotted as function of TC concentration as: (-•-) untreated control (0 ^M TC + 
100 ^M Cu (II)); (-A-) TC + 0 nM Cu (II); and (-•-) TC +100 jiM Cu (II). The 
inset shows the absolute amounts of salicylated products, as an index of 'OH radicals 
as determined, using a calibration curve of 2,3-dihydroxybenzoate, following the 
standard procedure mentioned in methods sections. The data points shown are the 
mean + S.D. of two independent experiments done in duplicate. 
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Table 9 
Effect of quenchers on tetracycline-induced ROS production and 
protein fragmentation. 
Quenchers 
(lOmM) • OH radicals 
Percent Inhibition 
O2 •" anions Protein fragmentation 
Control 
Mannitol 
Ethanol 
DMSO 
SOD (150 units) 
0.0 
83 ±3.8 
32 ± 2.4 
16 ± 4.9 
0.0 
0.0 
67 ± 7.0 
0.0 
61 ± 6.5 
n.d. 
n.d. 
11 ±0.8 
Figure 24. SDS-PAGE of photoexcited tetracycline treated BSA. The 
degradation pattern of treated protein at increasing concentrations (0-2 
mM) of TC in presence of 100 )aM Cu (II) ions is shown in the gel 
photograph. Lanes from left to right indicate as: lane 1, Standard mol. 
wt. markers, including BSA, ovalbumin, (OA); chymotrypsin (Chy); 
cytochrome C (Cyt C); lane 2, BSA alone; lane 3, BSA + 0.5 mM TC + 
Cu (II); lane 4, BSA + 1 mM TC + Cu (II); lane 5, BSA + 2 mM TC + 
Cu (II). 
1 2 3 4 5 
BSA 
Ova 
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concentration dependent fragmentation of protein was noticed. Treatment of 
albumin with photoexcited tetracycline in presence of Cu (II) enhanced the extent 
of fragmentation. Compared to the untreated albumin band in lane 2, a discernible 
reduction in the intensity of protein bands with concomitant generation of satellite 
bands in lanes 3 to 5 were noticed. Photoexcitation of tetracycline alone does 
induce fragmentation but was no detectable on SDS-PAGE gel. However, the 
quantitative spectrophotometric assays demonstrated significant release of acid 
soluble amino groups and carbonyl groups from the fragmented protein using 
glycine and acetophenone, respectively as standards. The extent of fragmentation 
in the lower concentration range of 0-1 mM tetracycline is shown in Figure 25. 
An increase in the absorbance of color at 335 nm indicates the tetracycline dose 
dependent release of acid soluble amino groups. The absolute amounts of acid 
soluble amino acids released are shown in the inset of Figure 25. Interestingly, the 
presence of 100 |iM Cu (II) ions in the reaction mixture during protein treatment 
with photoexcited tetracycline enhanced the protein fragmentation by 23 percent. 
Also, the photoexcitation time dependent increase in the intensity of yellow color, 
formed due to reaction of acid soluble amino groups with TNBS reagent, was 
observed upon photoexcitation of fixed concentration of tetracycline (200 juM) 
plus Cu (II) (100 |xM). The absorbance at 335 nm was found to be reduced 
substantially (61 %) in presence of 10 mM mannitol, used as a 'OH quencher 
(Figure 26). Furthermore, a linear increase in the absorbance of red wine color, 
developed due to carbonyl groups, was noticed up to 400 jiM tetracycline at 480 
E 
c 
CO 
d> 
o 
c 
(0 
n 
o 
w 
< 
200 400 600 800 1000 
Tetracycline concentration {\M) 
Figure 25. Quantitative assessment of protein fragmentation induced with photoexcited 
tetracycline. BSA in presence of TC at the indicated concentrations was photoexcited as 
described in methods. The absorbance and absolute amounts of acid soluble amino groups 
released upon protein fragmentation at varying TC concentrations in presence (-•-) and 
absence (-A-) of Cu (H) ions were plotted along with the untreated control (-•-). Each point 
represents the mean +_S.D. of two independent experiments done in duplicate. 
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Figure 26. Effect of free radical quenchers on time dependent protein 
fragmentation. The amount of acid soluble amino groups released upon 
photoexcitation of tetracycline was measured as described in the methods. 
The absorbance was monitored at varying photoexcitation time and plotted 
as (-•-) untreated control; (-•-) TC + Cu (II), and (-A-) TC + Cu (II) 
+ 10 mM mannitol Each data point represents the mean + S.D. of two 
independent experiments done in duplicate. 
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nm (Figure 27). Compared to tetracycline alone, at ImM concentration, the 
albumin treated with tetracycline-Cu (II) exhibited almost 27% increased release 
of carbonyl groups. 
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Figure 27. Carbonyl contents of BSA following exposure to photoexcited 
tetracycline. The change in absorbance measured at varying TC 
concentrations in presence (-•-) and absence (-A-) of Cu (II) ions were 
plotted. The inset shows the absolute amount of carbonyl groups as a 
function of TC concentration. Each point represents the mean ± SD of two 
independent experiments done in duplicate. 
89 
4. Discussion 
The phototoxicity and DNA damaging potential of tetracyclines are well 
documented (Hasan et al., 1984, Buschfort & Witte, 1994). However, the extent 
and nature of damage in proteins exposed to photoexcited tetracycline and the role 
of metal ions in tetracycline induced macromolecular alterations have not been 
thoroughly addressed. Therefore, in the present study, the extent of protein 
damage inflicted with photoexcited tetracycline was determined and the role of 
tetracycline-Cu (II) induced 02*" and "OH in protein fragmentation has been 
elucidated. The data revealed significant fragmentation of albumin upon treatment 
with photoexcited tetracycline both in the absence and presence of 100 |iM Cu (II) 
ions. Indeed, the Cu (II) ions significantly enhanced the fragmentation process as 
evident from the noticeable reduction in the intensity of protein bands with 
concomitant development of some auxiliary bands on SDS-polyacrylamide gel. 
Apparently the sum of the intensity of all auxiliary bands of protein fragments 
were found to be equal to the band intensity of untreated albumin. Indeed, the 
development of distinct bands at higher tetracycline-Cu (II) combinations reflects 
the site-specific nature of cleavage in protein chain. These results unequivocally 
suggest the fragmentation of albumin upon exposure to white light in presence of 
higher concentrations (0.5 to 2 mM) of tetracycline. Furthermore, the release of 
acid soluble amino groups and carbonyl groups from treated albumin confirmed 
the fragmentation of protein both in the absence and presence of Cu (II) ions. 
These results signify considerable amount of protein damage even at lower 
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tetracycline concentrations, while the damage was not discemable on the gel. The 
quantitative spectrophotometric data indicate that the protein degradation may be 
due to the peptide bond hydrolysis and/or chain scission at a-carbon position. 
Our free radical quenching studies clearly suggests the involvement of free 
radicals in protein fragmentation process during photoexcitation reaction. The 
increased production of 'OH upon photoexcitation in presence of Cu (11) ions as 
well as a noticeable reduction in the amount of both the • OH and acid soluble 
amino groups released from treated albumin in presence of 10 mM mannitol 
suggests a potential role of -OH in protein fragmentation. The enhanced "OH 
generation with tetracycline-Cu (II) complex may be due to the chelation of Cu 
(II) ions with tetracycline molecule at neutral pH and its subsequent redox-
reaction. The Cu (II) ions are known to form a complex with the oxygen bound at 
carbon-3 and amide group and/or oxygen atoms bound at C-10 and C-11 positions 
of tetracycline, and undergo concomitant reduction with the oxidation of 
tetracycline (Buschfort & Witte, 1994). It is likely that an electron transfer from 
tetracycline to bound Cu (II) occurs and subsequent reoxidation of Cu (I) ions 
results in the formation of reactive oxygen species. Also the reaction of free 
electrons ejected by photoexcited tetracycline with molecular oxygen renders the 
generation of 02*" anions. Simultaneously, the photo-dissociation of dimethyl-
amino group of tetracycline upon reaction with molecular oxygen also produces 
peroxide radical at position-4 on the aromatic rings. The 02"' anions and peroxide 
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radicals generated with photoexcited tetracycline upon Fenton-type decomposition 
generate -OH radicals (Davies et al, 1979; Green & Hill, 1984; Halliwell & 
Aruoma, 1991; Halliwell & Gutteridge, 1992). It is likely that the production of 
these • OH radicals in close proximity of protein with bound tetracycline-Cu (II) 
may attack the susceptible aromatic moieties on proteins resulting in the site-
specific cleavage. Our studies have demonstrated the binding of tetracycline with 
serum albumin (Khan et al. 1998). Particularly, the aromatic amino acids such as 
tryptophan and tyrosine, as well as cysteine have been suggested to be involved in 
drug-albumin interactions. The data also suggested that the superoxide anions and 
peroxyl radicals induce a non-specific damage resulting in the release of acid 
soluble products from tetracycline treated protein. However, the larger protein 
fragments generated due to site-specific cleavage by "OH radicals were co-
precipitated along with the intact unhydrolysed protein in spectrophotometric 
assays, and therefore, does not contribute in the overall absorbance of released 
acid soluble products. 
These results have ascertained a dose dependent relationship between the free 
radicals (02"' and 'OH) production and tetracycline photoexcitation. Moreover, 
the increased fragmentation of albumin and "OH radicals generation with the 
addition of Cu (II) ions reflects the role of metal ions in augmenting tetracycline-
induced toxicity. The higher extent of protein damage with the addition of Cu (II) 
may pose a risk of macromolecular damage, specifically in individuals with 
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Wilson's disease (Marsden, 1987). This genetic disorder of copper metabolism 
causes an elevated levels of free copper in the plasma, liver, kidney, brain and 
bone marrow cells (Marsden, 1987). Also the women bearing a copper containing 
intrauterine pessar (lUP), from which approximately 50 ^g of copper is leached 
per day, could be the susceptible targets. Comparative studies on the effect of 
other clinical tetracyclines viz. DOTC, OTC, DMTC, CTC, and MC in 
combination of Cu (II) ions on target organisms and/or cells lines may cause 
epigenetic alterations and promutagenic lesions in cellular macromolecules. 
CHapter 1^ 
Interaction 
of 
1. Introduction 
Studies on the binding of various drugs, dyes and antibiotics to DNA and 
chromatin have contributed substantially to understanding of their mode of action 
and site-specificity. In general, the absorbance (Calendi et al., 1965; Gabbay et al., 
1976) and fluorescence (Tsou & Yip, 1976, Plumbridge & Brown, 1977) titration 
techniques have been used to examine the interactions of ligand chromophores 
with nucleic acids. These techniques depend upon the demonstration of spectral 
alterations of the ligand upon interaction with nucleic acids (Peacocke & Skerrett, 
1956). Such alterations have been previously reported for daunomycin (Calendi et 
al., 1965) and adriamycin (DiMarco et al., 1975) 
Binding of tetracyclines to DNA in the presence of divalent cations have 
also been reported (Kohn, 1961). The divalent metal ions play an important role in 
modulating the biological and biochemical effects of the tetracycline. These 
effects include the inhibition of certain enzymes (Rokos et al., 1958), the 
precipitation of ^-lipoproteins (Lacko et al., 1959) and the localization of 
tetracyclines in tumor tissues (Rail et al, 1957). These phenomenon involves the 
formation of tetracycline-metal chelates (Albert, 1956). Earlier studies have 
demonstrated tetracycline chelation with multivalent cations and their interaction 
with human red cell membranes, lipids and a variety of proteins using 
fluorescence and circular dichroism measurements (Schneider et al, 1983). Some 
tetracyclines have also been used as fluorescent probes to demonstrate their 
preferential binding to cations on the membrane surfaces (Caswell & Hutchison, 
1971). Binding of drugs to DNA has also been analyzed by neighbor exclusion 
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monovalent cation concentration and ip is the fraction of a counter ion, which is 
thermodynamically bound per phosphate (Record et ai, 1976). Considering [M^] 
equal to [Na"^ ], the values for m' were determined. The value of ip as to 0.82, was 
used to represent the fraction of a counter ion, which is thermodynamically bound 
per phosphate in a native DNA-drug complex (Wilson & Lopp, 1979). 
2.3. Circular dichroism (CD) measurements 
CD spectra of tetracyclines alone and in combination with Cu (II) at the 
ratio of 1:2 were obtained both in the absence and presence of 100 |iM DNA in a 1 
cm path length cell. The CD measurements were carried out with a Jasco 
spectropolarimeter, model J-720. The instrument was calibrated with d-10-
camphorsulphonic acid. All the CD measurements were carried out at 25°C with a 
thermostatically controlled cell holder attached to a NESLAB RTE-110 circulating 
water bath (NESLAB Instruments, Inc. USA) with an accuracy of ± 0.1 °C. All the 
spectra were collected at a scan speed of 100 nm per minutes with a response time 
of 1 sec. Each spectrum was the average of three scans and corrected by 
subtraction of a buffered blank under identical conditions. The results expressed as 
molar ellipticity [0]x in deg.cm^.dmol'", which is defined as [0]x = 10 0/c d , 
where, 0 is the observed ellipticity in degrees, c is the concentration in mol/1 of 
total drug, and d is the path length in decimeters. 
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3. Results 
3.1. Quenching of tetracycline fluorescence upon binding with DNA 
The interaction of tetracyclines with calf thymus DNA was studied by 
monitoring the changes in the intrinsic fluorescence of tetracyclines at varying 
DNA/TC molar ratios. Figure 28 (A-C) shows the fluorescence emission spectra 
of TC, CTC and DMTC, respectively. These antibiotics exhibited significant 
spectral changes upon interaction with DNA in the wavelength ranges of 450-570 
nm, 450-550 nm and 450-600 nm, respectively. Addition of calf thymus DNA in 
increasing concentrations, to fixed amount of tetracyclines progressively 
decreased the fluorescence of TC, CTC and DMTC throughout the spectrum with 
no significant enhancement of any portion of the spectrum or peak shift. Since the 
highest change in the tetracyclines fluorescence spectra with the addition of DNA 
occurred at the wavelengths indicated in Table 10, the fluorescence measurements 
at these wavelengths yielded accurate determination of fraction of the total 
tetracyclines bound. The derivatives OTC and DOTC have produced much less 
quenching effect upon incubation with DNA compared to other derivatives. The 
relative fluorescence intensity for each derivative was determined from the 
corresponding spectra and plotted as a fiinction of DNA-TC molar ratio. Figure 29 
shows the comparative binding isotherms of tetracycline and its derivatives. At a 
DNA-drug molar ratio of 30, the percent quenching for TC, CTC, DMTC, OTC 
and DOTC was determined to be 64%, 47%, 36.5%, 15%, and 11% respectively. 
By assuming that the amount of fluorescence quenching is proportional to the 
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Figure 28. Emission spectra of tetracyclines in the absence 
(uppermost curve) and presence of increasing amounts of DNA. 
The molar ratios in each spectra are shown as (A) DNA to TC: 
0.0, OA 1.6, 3.2, 4.0, 6.0, 8.0, 10, 12, 14, 16, 20, 24, 28, 32, 36, 
40, (B) DNA to CTC: 0.0, 0.5, I.O, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10, 
14, 18, 20, 25, 30 and (C) DNA to DMTC: 0.0, 0.5, 1.0, 2.0, 4.0, 
6.0, 8.0, 10, 15, 20, 25, 30, 35, 40, 45, 50. The spectra were taken 
at the corresponding wavelengths for each derivatives as 
specified in Table 10. 
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Figure 29. Quenching of tetracyclines fluorescence upon DNA binding. 
Changes in the relative fluorescence of tetracyclines with the addition of 
DNA are represented as (-•-) TC, (-0-) CTC, (-•-) DMTC, (-A- ) 
OTCand(-^)DOTC. 
amount of tetracycline bound to DNA, the association constant Kg for different 
tetracyclines was calculated by Scatchard analysis (1949). Figure 30 A-C shows 
the corresponding Scatchard plots. The slope of the straight line drawn through the 
linear region of the plot provided the Kg values for each drug. The comparative 
binding data obtained from the Scatchard plots are shown in Table 11. The Ka 
values for TC, CTC and DMTC were determined to be 1.16 x 10^ 3.4 x 10^  and 
3.04 X lO'' litre/mole, respectively. Values of the parameter n, which is a measure 
of the number of binding sites of DNA for tetracycline were calculated from the 
intercepts of the straight lines on the X-axis. The variations in the value of n for 
the tetracycline derivatives account for the differences in their chemical reactivity 
due to structural variations. 
3.2. Effect of ionic strength on DNA-tetracycline binding 
To determine the contribution of electrostatic interactions in the overall 
binding of tetracyclines with DNA, the fluorescence quenching of tetracyclines 
was measured in solutions of varying ionic strengths. Figures 31 and 32 show the 
binding isotherms and Scatchard analysis of TC-DNA interactions in presence of 
NaCl at varying concentrations. The results indicate a significant decrease in the 
affinity of DNA binding for tetracycline at higher ionic strengths, particularly at 
50 and 200 mM NaCl without significantly altering the capacity of binding (Figure 
31). The quenching of tetracycline fluorescence was reduced by 27% and 42% at 
1:12 DNA-TC molar ratio in presence of 50 and 200 mM NaCl, respectively. Any 
increase beyond this molar ratio does not enhance the quenching effect. 
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Table 11 
Binding parameters of tetracyclines with calf thymus DNA 
Drugs KaX 10\litre/mole) nxlO' 
TC 1.16 1.53 
CTC 3.40 0.82 
DMTC 3.04 0.54 
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Figure 31. Binding isotherm showing the effect of ionic strength on DNA 
- induced quenching of tetracycline fluorescence in the presence and 
absence of NaCl.The curves represent as (-•-) DNA-TC (without NaCl), 
(-O-) DNA - TC with 5 mM, (-^) DNA - TC with 50 mM and 
(-A-) DNA-TC with 200 mM NaCl.The excitation and emission 
wavelength were 390 nm and 525 nm, respectively. 
Figure 32. Scatchard analysis of DNA binding with TC at increasing 
ionic strength. The plots represent as (A) 0.0 mM, (B) 5 mM, (C) 
50 mM and (D) 200 mM NaCl. 
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Comparative binding parameters obtained at specific concentrations of 5, 50 and 
200 mM NaCl are shown in Table 12. The binding constant (Kg) exhibits a linear 
relationship with Na"^  ion concentration, when log Kg was plotted as a function of 
-log[Na^] (Figure 33). The number of ion pairs formed between TC and DNA 
(m') was determined to be 0.675. 
3.3. Effect ofCu (II) ions on DNA-inducedfluorescence quenching of 
tetracyclines 
Figure 34 shows the representative fluorescence emission spectra of 
tetracycline upon addition of DNA in presence and absence of 10 jiM Cu (II) ions. 
Considering the fluorescence intensity value of TC alone as 100%, the extent of 
quenching at a Cu (II)-TC molar ratio of 2:1 was determined to be 28%. However, 
the intrinsic fluorescence of TC in combination with DNA alone and DNA-Cu (II) 
decreased to the extent of 39 % and 74 %, respectively (Figure 34). The results 
clearly exhibit significant DNA-Cu (II) mediated tetracycline fluorescence 
quenching as compared to DNA or Cu (II) alone. The quantitative data reflecting 
the quenching effects of tetracycline fluorescence with increasing DNA 
concentration in the presence of 1, 5 and 10 |xM Cu (II) ions are shown in Figure 
35. The corresponding Scatchard plots and binding parameters are shown in 
Figure 36 (A-D) and Table 13. The presence of Cu (II) at higher concentrations in 
the binding reaction results in the reduction of Ka and binding capacity of 
tetracycline with DNA. 
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Table 12 
Effect of ionic strength on tlie binding parameters of TC with calf thymus 
DNA 
NaCl (mM) 
0.0 
5 
50 
200 
Ka X 10\litre/mole) 
1.16 
1.00 
0.77 
0.46 
nxlO'2 
1.53 
1.50 
1.61 
1.34 
o 
- log [NaT 
Figure 33. Relationship of the binding constant (KJ with ionic strength. 
The log binding constant (KJ values obtained for the TC - DNA 
interactions at varying NaCl concentrations of 5, 50 and 200 mM are 
plotted as a function of-log[Na^]. 
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Figure 34. Effect of Cu (II) on tetracycline fluorescence. TC 
fluorescence was measured in absence and presence of 200 \iM 
DNA and 10 yM Cu (II). The spectra represent as (1) TC alone, 
(2) TC + Cu (II), (3) TC + DNA and (4) TC + Cu (H) + DNA. 
Excitation wavelength at 390 nm. 
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Figure 35. Quenching effect of DNA on tetracycline fluorescence 
in presence of Cu (II) ions. The molar ratio of DNA to TC: 0.0, 0.8, 
1.6, 3.2, 4.0, 8.0, 12, 16, 20, 24, 28, 32 and 36. The curves represent 
as (-•-) control (0.0 uM Cu (II)), (HD-) 1 uM, (-A-) 5 uM and 
( - ^ ) 10 uM. 
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Figure 36. Scatchard analysis of TC - DNA binding in the presence of Cu (II) ions. 
The plots represent as: (A) 0.0 uM, (B) 1 uM, (C) 5 uM and (D) 10 uM, respectively. 
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Table 13 
Effect of copper ions on the binding parameters of tetracycline with DNA 
Cu (II) ions Ka X 10^  (litre/mole) n x 10' 
(^ iM) 
0 1.16 1.53 
1 1.08 1.92 
5 0.96 1.70 
10 0.72 1.06 
2 
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3.4. Circular dichroism of tetracyclines-DNA complexes 
The circular dichroism spectra of tetracycHnes in the absence and presence 
of DNA and Cu (II) ions are shown in Figure 37. The CD spectrum of TC shows a 
characteristic positive band at 294 nm and two negative bands at 248 nm and 326 
nm, respectively. At least two regions of the spectra were found sensitive to the 
copper ions. These two spectral regions lies in the vicinity of 304 nm (+ve), which 
was red shifted by 10 nm and 338 nm (-ve) band, with a red shift by 12 nm with 
two additional peak at 373 nm and 405 nm. Addition of DNA to the TC-Cu (II) 
complex shows disappearance of the positive and negative CD bands at 373 nm 
and 405 nm, respectively. In addition slight shifts in -ve bands have been noticed 
with TC-Cu (II) complex. Tetracycline in presence of Cu (II) and DNA separately 
as well as in combination exhibits significant reduction in ellipticity. CD spectra 
of tetracycline, Cu (II) and DNA exhibit an isosbestic point at 383 nm. Similarly 
the CD spectra of tetracycline derivatives with Cu (II) ions in the absence and 
presence of DNA are shown in Figures 38-41. Invariably, all the derivatives of 
tetracycline showed change in ellipticity upon binding with DNA in the presence 
of Cu (II) ions. 
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Figure 37. CD spectra of tetracycline (50 \iM) in 10 mM Tris-HCl buffer, pH 
7.4 in the absence and presence of 100 \iM Cu (II) and 100 ^M DNA. The 
spectra represent (1) TC alone, (2) TC + Cu (II) and (3) TC + Cu (II) + DNA. 
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Figure 38. CD spectra of chlorotetracycline (50 |iM) in 10 mM Tris-HCI buffer, 
pH 7.4 in the absence and presence of 100 ^M Cu (II) and 100 ^M DNA. The 
spectra represent (1) CTC alone, (2) CTC + Cu (II) and (3) CTC + Cu (II) + 
DNA. 
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4. Discussion 
In this study, the interaction of tetracyclines with calf thymus DNA has 
been studied by fluorescence spectroscopy and circular dichroism. The data 
revealed that the intrinsic fluorescence of tetracycline and its derivatives quenched 
to a significant extent upon interaction with DNA. This may be due to masking or 
burial of tetracycline chromophores upon intercalation between the stacked bases 
with in the helix and/or surface binding at the reactive nucleophilic sites on the 
heterocyclic nitrogenous bases of DNA molecule. It is likely that the insertion of 
planar naphthacene ring of tetracyclines may occur between the adjacent bases of 
DNA duplex. It could be similar to the intercalation of structurally analogous 
anthracycline ring as reported in case of anthracyline-DNA interaction (Lerman, 
1961). The intercalation of planar molecules in between the stacked bases is 
known to cause alterations in the secondary structure of native DNA duplex. This 
corroborates well with the DNA secondary structural changes observed upon 
tetracycline-DNA binding. Our studies mentioned in chapter VI also clearly 
demonstrated the helix opening and formation of Si nuclease sensitive sites in 
tetracycline-modified DNA, which is most likely due to intercalating effect of 
tetracyclines. In addition to possible intercalative binding process, the 
fluorescence data also implicates weaker electrostatic interactions of tetracyclines 
with DNA. Such interactions resulted in the formation of TC-DNA binary 
complex. The binding studies revealed a significantly higher association constant 
(Ka= 1.16 X 10^  M'^ ) between tetracycline and DNA, which clearly suggested 
strong affinity of the drug towards DNA. Similarly, the data obtained from the 
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Scatchard plots of three representative tetracycline derivatives, implied that the 
extent of binding varies among the tetracycline derivative due to subtle differences 
in their reactive functional groups. Comparison of the binding constants (Ka), 
revealed that the binding affinities vary in the order as CTC>DMTC>TC. The 
lesser binding of the parent compound (TC) with DNA vis-a-vis the derivatives 
CTC and DMTC implies the role of functional groups present on the naphthacene 
ring system. The derivatives, CTC and DMTC contains a halogen moiety at C-7 
position on the D-ring of naphthacene ring system, which might be a contributing 
factor for their relatively stronger binding affinities. However, the change in 
number of binding sites of subsfituted tetracyclines on DNA molecules reflects the 
relative capacity of tetracycline derivatives to form DNA-TC adducts. 
Another factor that influences the drug-DNA interaction is the relative 
stability of the DNA duplex. Amongst the forces destabilizing the helical structure 
of DNA in a solvent includes the phosphate-phosphate repulsions in the DNA 
molecule (Larcom et al.,\9Sl). This effect can be overcome by counter balancing 
the charge on the phosphate groups of DNA with the Na"^  ions. Interestingly, the 
binding affinity of tetracycline with DNA decreases substantially in the reaction 
buffers containing NaCl at higher molarities. This could be attributed to poor 
accessibility of the binding sites on DNA for tetracycline functional groups to bind 
in presence of Na^ ions. Also the DNA molecule undergo significant 
conformational change at higher NaCl concentrations. This may reduce the extent 
of drug intercalation under higher ionic strength conditions. Earlier studies also 
demonstrated that at higher concentration of NaCl, the monovalent Na"*" ions 
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exhibit a tendency to coordinate with purines, pyrimidines and phosphate groups 
of DNA, and decreases the unpairing of bases leading to conformational 
modification of the DNA molecule (Perahia, et al., 1977; Larcom et al, 1981). 
However, relatively higher binding affinity of tetracycline towards DNA under 
low ionic strength conditions, implicates the role of electrostatic forces in the 
DNA-TC interactions. 
The fluorescence quenching of tetracycline was also found to be decreased 
significantly in presence of divalent metal ion Cu (II). This could be due to the 
preferential binding of Cu (II) with tetracycline. There are two potential Cu (II) 
binding sites reported on tetracycline molecule (Buschfort & Witte, 1994). The Cu 
(II) ions form complex with the oxygens bound at C-3 and amide group as well as 
the oxygen atoms bound at C-10 and C-11 positions. Presumably, this is attributed 
to the slight reduction of binding affinity of tetracycline with DNA in presence of 
Cu (II). However, the tetracycline-Cu (II) complex upon interaction with DNA 
transforms into a tetracyline-Cu (II)-DNA ternary complex. The CD data 
exhibiting substantial changes in the ellipticity values clearly suggested the 
structural alterations in drug and formation of DNA-TC-Cu (II) ternary 
complexes. These ternary complexes may indirectly enhance the surface binding 
of tetracylines to DNA due to metal ion bridge formation. The role of metal ion 
bridges in enhancing the binding of tetracycline with proteins has been 
demonstrated (Kohn, 1961). The interactions of the ligands most likely involve the 
guanine, cytosine and phosphate groups of DNA (Zimmer et al, 1971; Forster et 
al, 1979). Thus, in addition to surface binding of tetracycline on DNA, the 
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intercalation of tetracycline may induce substantial conformational changes in the 
DNA structure. 
The presence of divalent metal ions is known to contribute in several 
biological and biochemical effects of the tetracycline antibiotics. For instance, 
calcium chelation may account for the binding of tetracyclines in newly formed 
bone (Milch et al., 1958), and retention of antibiotics in calcified tissues (Rail et 
a/.,1957; DuBuy & Showacre, 1961). Also the antibacterial activity of the 
tetracycline is related to stability of the tetracycline-metal complex. Our 
fluorescence and CD data reflecting spectral changes in the tetracyclines upon 
binding with DNA and Cu (II) ions, elucidate the significance of tetracycline, 
DNA and Cu (II) interactions related to genotoxicity and cytotoxicity. In 
conclusion, the present study demonstrates that the tetracyclines can act both as 
surface binder and intercalator, involving the electrostatic and hydrophobic 
binding forces. More hydrophobic tetracyclines such as DMTC, CTC and TC may 
preferably intercalate into the helix, whereas others derivatives may participate in 
surface binding on DNA molecule. Although, the in vivo situtation is considerably 
more complicated due to problems of permeability, solubility, competitive binding 
to proteins and/or lipids and metabolic breakdown of the drugs, the in vitro data 
provided important biophysical information related to drug-DNA interactions. It is 
surmised that irrespective of the nature of interaction, the binding of tetracyclines 
and Cu (II) causes perturbations in the secondary structure of DNA, which may be 
detrimental if the DNA damage is not accurately repaired under intracellular 
conditions. 
CHapter Vl 
®5Vy? damage 
1. Introduction 
Tetracyclines are the broad spectrum antibiotic, commonly used in the 
treatment of various bacterial infections and acne. In addition to their 
pharmacological action spectra, tetracyclines are known to exhibit phototoxicity. 
UV exposure to tetracyclines promotes its oxidative degradation and generates 
hydroxyl radicals (Davies et al, 1979; Green & Hill, 1984) and singlet oxygen 
(Sanderberg et al, 1984; Li et al, 1987). These tetracycline mediated reactive 
species are reported to cause photohemolysis of erythrocytes (Nilsson et al, 1975) 
and initiate damage to ribosomes (Rebout et al, 1982; Goldman et ah, 1983). Both 
the hydroxyl radicals and singlet oxygen are known to damage the proteins (Kohn, 
1961) and also induce strand breaks in DNA (Epe et al, 1989; Halliwell & 
Aruoma, 1991). Few studies on tetracycline-induced DNA damage also reported 
the formation of single strand breaks both upon UVA irradiation and in dark in the 
PM 2 and bacteriophage cpx 174 DNA (Piette et al, 1986; Buschfort & Witte, 
1994). 
In general, the oxygen and nitrogen sites on nitrogenous bases in DNA 
have been reported to be quiet reactive, and readily under go alkylation (Singer & 
Grunberger, 1983). Lawley and Brookes (1963) have demonstrated that the main 
alkylation sites in duplex DNA are the N-7 of guanine and N-3 of adenine. In 
addition, the alkylation of DNA phosphates may also occur. Also, the ratio of 
oxygen versus nitrogen alkylation has been reported to be significantly different 
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with the methylating agents, causing ~ 80% N-methylation and ~ 20% O-
methylation (Singer, 1985). 
It is speculated that the methyl groups present at C-4 and C-6 positions on 
tetracycline molecule may participate in DNA alkylation process. However, the 
molecular mechanism of tetracycline interactions with DNA and alkylation, if any, 
has not been reported. Although, earlier studies have demonstrated the strand 
breakage by tetracycline but virtually no information on dose dependent DNA 
damage with tetracycline derivative and metal ion participation in strand cleavage 
is available in literature. This prompted us to investigate the possibility of 
alkylation and induced strand breaks in DNA with a suggestive mechanism, upon 
exposure to tetracyclines and Cu (II) ions. The study clearly demonstrates 
tetracycline mediated DNA alkylation leading to GC to AT base mismatching. 
Also extensive DNA damage may occur in parallel due to free radical generation 
following reduction of tetracycline-bound Cu (II) to Cu (I) under in vitro 
conditions. 
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2. Materials and Methods 
2.1. Reaction of tetracyclines with calf thymus DNA and digestion with Sj 
nuclease 
Calf thymus DNA (500 ^g) in 10 mM Tris-HCl, pH 7.4 was treated with 
increasing concentrations of tetracycline to obtain the molar ratios of 1:0.5, 1:1, 
1:2, 1:4, 1:8 and 1:12 in presence of 100 |iM Cu (II) ions. The reaction mixture 
was exposed to white light for 2 h at room temperature. Subsequently, Si nuclease 
buffer (0.1 M acetate buffer, pH 4.5 containing 1 mM ZnS04) and Si nuclease (30 
U) were added to each tube. The tubes were then incubated at 48°C for 2 h. BSA 
(2 mg) was then added to each tube followed by 1 ml of 14% PC A. The tubes 
were quickly transferred to an ice bath and kept at 4°C for 1 h. The supernatant 
was recovered after centrifiigation at 2500 rpm for 30 min and the acid soluble 
deoxyribonucleotides were determined according to the method of Schneider 
(1957). 
2.2. Alkaline hydrolysis of tetracyclines treated DNA 
Calf thymus DNA (500 ng/ml) was treated with tetracyclines in DNA 
nucleotide/tetracyclines molar ratio range of 1:0.5 to 1:12. The reaction mixture 
was exposed to white light for 2 h in presence of 100 |iM Cu (II). Parallel control 
without tetracycline was run under identical conditions. The pH of the reaction 
mixture at the end of the incubation was measured and found unchanged. 
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Photosensitized tetracycline-Cu (II) treated DNA was separatel)' incubated with 
0.1 M and 0.5 M NaOH for 1 h to determine the alkali labile sites in DNA. The 
DNA was then precipitated by adding 1ml of cold 14% perchloric acid in the 
presence of 0.2 ml of 10 mg/ml bovine serum albumin at 0°C. The precipitated 
DNA was centrifuged at 2500 rpm for 30 min and the pellet was discarded. The 
acid soluble nucleotides were estimated in supernatant according to the method of 
Schneider (1957). 
2.3. Alkaline unwinding assay 
Strand breaks in cellular DNA were quantitated by alkaline unwinding 
assay using hydroxyapatite batch procedure (Kanter & Schwartz, 1979). In brief, 
the calf thymus DNA (100 jig) in a volume of 0.5 ml in multiple sterile tubes were 
treated with tetracycline in the desired DNA nucleotide/tetracycline molar ratios. 
The reaction mixtures were incubated at 37°C, exposed to white light. The tubes 
were immediately placed on ice and subjected to alkaline unwinding by rapid 
addition of an equal volume of 0.06 N NaOH in 0.01 M Na2HP04, pH 12.5 
followed by brief vortexing. Alkaline unwinding was allowed to be completed in 
dark for 30 min. The pH of the reaction mixture was then neutralized to pH 7.0 
with the addition of 0.068 N HCl. Subsequently, 20 ^M EDTA containing 2% 
SDS was added and mixed thoroughly. The resultant mixture was then transferred 
to preheated stoppered glass tubes containing 0.5 M potassium phosphate buffer, 
pH 7.0 and 10% formamide. The samples were incubated at 60°C for 2h with 
intermittent vortexing. The relative amount of duplex and single stranded DNA 
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present at the end of the alkaline unwinding was quantitated. Single stranded DNA 
was selectively eluted from the hydroxyapatite matrix with 0.125-M potassium 
phosphate buffer, pH 7.0 containing 20% formamide. However, duplex DNA was 
removed with 0.5 M potassium phosphate buffer, pH 7.0 containing 20% 
formamide. The DNA in the eluates was measured and strand breaks were 
estimated following the equation In F = - K/Mn . tP, where F is the fraction of 
remaining double stranded after alkali treatment for the time t, Mn is the number-
average molecular weight between two breaks and 3 is a constant that is less than 
one (Rydberg, 1980). The number of unwinding points (P) per alkaline unwinding 
unit of DNA were calculated according to the equation, P = In ¥J\n Fo (Kanter & 
Schwartz, 1979) where, Fx and FQ are the fractions of double stranded DNA 
remaining after alkaline denaturation of treated and untreated samples, 
respectively. The number of breaks (n) per unit DNA were then determined using 
equation n = P-l 
2.4. Hydroxyapatite chromatography 
Hydroxyapatite chromatography was performed following the procedure of 
Bemardi (1971). The native and tetracycline treated calf thymus DNA (500 \ig) 
were applied to the hydroxyapatite column ( 3 x 1 cm). The elution started with a 
step-wise gradient of sodium phosphate buffer, pH 7.0 of 0.1, 0.15, 0.2, 0.25, 0.3 
and 0.35 M. Fractions of 1 ml were collected at the rate of 5 ml/h. The DNA 
eluted in various fractions were determined by the diphenylamine method of 
Schneider (1957). 
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2.5. Plasmid nicking assay 
Covalently closed circular plasmid pBR 322 DNA (0.25 |ig) in a final 
volume of 30 |u,l were treated with varying concentrations of tetracycline (0.1- 2.0 
mM) in the absence and presence of Cu (II) ions and exposed to white light for 2h. 
To this, 6 i^l of 5X tracking dye (40 mM EDTA, 0.05 % bromophenol blue and 50 
% (v/v) glycerol) was added and loaded onto 0.8 % agarose gels. The gel was run 
at 50 mA for 3 h and stained with ethidium bromide (0.5 )ig/ml), for 30 min at 
4°C. After washing, the bands were visualized on UV-transilluminator 
(Photodyne, USA.) and photographed. 
2.6. Stoichiometric titration ofCu (I)production 
The amount of Cu (I) produced during TC-Cu (II) reaction was determined 
upon titration with bathocuproine disulfonic acid (BCS). Briefly, 12.5 and 25 p,M 
tetracyclines in 10 mM Tris-HCl buffer, pH 7.4 were mixed with CuCl2 at varying 
molar ratios in the presence of constant amount (0.3 mM) of bathocuproine in a 
total volume of 1 ml. The extent of bathocuproine-Cu (I) complex formation at 
increasing Cu (II)-TC molar ratios was determined by measuring absorbance at 
480 nm. 
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3. Results 
3.1. Sj nuclease hydrolysis oftetracycline-Cu (II) treated DNA 
Treatment of DNA with tetracycline at increasing molar ratios in the 
presence of Cu (II) ions results in the formation of Si nuclease sensitive sites. The 
amount of acid soluble nucleotides released from Si nuclease treated DNA, 
increases with increasing tetracycline concentrations. Untreated native DNA used 
as negative control has not shown any significant hydrolysis, whereas the 
denatured DNA as a positive control exhibited 99% hydrolysis upon Si nuclease 
digestion. At the highest DNA nucleotide-TC molar ratio of 1:12 approximately 
25% hydrolysis was noticed (Table 14). Indeed, the percentage of DNA hydrolysis 
was observed to be dependent on the number of Si nuclease susceptible sites 
formed. Table 15 shows the comparative DNA damaging potential of tetracycline 
derivatives based on the Si nuclease susceptible and alkali-labile sites formation. 
A differential pattern of acid soluble nucleotides, released from treated DNA, was 
obtained. The DNA damaging capability of tetracycline derivatives varied in the 
order as DOTC>DMTC>TC>OTC>CTC at a fixed DNA nucleotide/tetracyclines 
molar ratio. Also a significant inhibition of Si nuclease hydrolysis oftetracycline-
Cu (II) treated DNA was noticed with the addition of increasing amounts of 
neocuproine as a Cu (I) chelating agent (Figure 42). The percent inhibition of 
DNA hydrolysis was calculated as [100 x (A-B)/A], A and B are the percent DNA 
hydrolysis values obtained without and with neocuproine, respectively. At a 
neocuproine-Cu (II) ratio of 2.0, almost 100% inhibition of DNA degradation was 
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Table 14 
Hydrolysis of tetracycline-Cu (II) treated DNA with Si nuclease 
DNA nucleotide/TC 
molar ratio 
Native DNA 
Denatured DNA 
1:0.5 
1:1 
1:2 
1:4 
1:8 
1:12 
Acid soluble DNA 
nucleotides (^ ig) 
18 
498 
62 
66 
70 
76 
103 
125 
% DNA hydrolysis 
3.60 
99.6 
12.4 
13.2 
14.0 
15.3 
20.7 
25.0 
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Table 15 
Comparative assessment of DNA hydrolysis upon tetracyclines-Cu (II) 
treatment 
DNA/ 
Drugs 
Native DNA 
Denatured DNA 
DNA + TC 
DNA + OTC 
DNA + CTC 
DNA + DOTC 
DNA + DMTC 
Percent 
Si nuclease 
3.50 
99.3 
22.3 
11.8 
7.40 
27.0 
26.0 
hydrolysis 
O.lMNaOH 
00 
00 
58 
49 
43 
76 
43 
c 
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Figure 42. Inhibition of S, nuclease DNA hydrolysis in presence of 
neocuproine. DNA treated with TC-Cu (II) at molar ratio (-0-) 1.1 
and (-A-) 2:1 were subjected to Sj nuclease digestion in presence of 
varying concentrations of neocuproine. 
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estimated. Also, the Si nuclease catalyzed hydrolysis of tetracycline-Cu (II) treated 
DNA was significantly reduced with free radical quenchers. Specifically, the ' OH 
radical quenchers viz. sodium benzoate, thiourea and mannitol caused 47 to 57% 
inhibition of Si nuclease hydrolysis respectively (Table 16). On the contrary, the 
catalase, superoxide dismutase and sodium azide as potential inhibitors of 
hydrogen peroxide, superoxide and singlet oxygen production showed negligible 
inhibitory effects on DNA hydrolysis. 
3.2. Alkaline hydrolysis oftetracyclines-Cu (II) treated DNA 
Alkaline hydrolysis of tetracyclines-Cu (II) treated DNA with 0.1 M and 
0.5 M NaOH exhibited progressive increase in the amount of acid soluble 
nucleotides released (Tables 17-21). At the highest DNA nucleotide/tetracycline 
molar ratio of 1:12, the percent hydrolysis was estimated to be 62, 46, 53, 82 and 
47% with 0.1 M and 76, 50, 64, 86 and 56% with 0.5 M NaOH, for TC, CTC, 
OTC, DOTC and DMTC, respectively. Under identical conditions, no hydrolysis 
was seen in the untreated control DNA. Comparative data on alkaline hydrolysis 
of DNA treated with tetracycline and its derivatives with 0.1 M NaOH and Si 
nuclease are shown in Table 15. 
5.5. Tetracycline-Cu (II) induced strand breaks in DNA 
The results of alkaline unwinding assay are shown in Figure 43. The data 
indicate tetracycline concentration dependent decrease in the fraction of duplex 
DNA with concurrent increase in the degree of single strandedness in DNA. Based 
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Table 16 
Effect of free radical quenchers on Si nuclease hydrolysis of tetracycline-Cu 
(II) treated DNA 
Free radical scavengers (%) Inhibition 
Catalase(100U/ml) 6.7 
Superoxide dismutase (lOOU/ml) 16.7 
Sodium azide(lOmM) 3.30 
Sodium benzoate (1 OmM) 51.0 
Thiourea (lOmM) 57.0 
Mannitol (lOmM) 47.0 
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Table 17 
Alkaline hydrolysis of tetraeycline-Cu (II) treated DNA 
DNA nucleotide/TC 
molar ratio 
Native DNA 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
1:12 
O.lMNaOH 
Acid soluble 
nucleotides 
(1^ 8) 
00.0 
80.0 
90.0 
103 
117 
122 
130 
145 
155 
% DNA 
hydrolysis 
00.0 
32.0 
36.0 
41.2 
46.8 
48.8 
52.0 
58.0 
62.0 
0.5 M NaOH 
Acid soluble 
nucleotides 
00.0 
80.0 
95.0 
113 
130 
150 
160 
175 
190 
%DNA 
hydrolysis 
00.0 
32.0 
38.0 
45.2 
52.0 
60.0 
64.0 
70.0 
76.0 
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Table 18 
Alkaline hydrolysis of chlorotetracycline-Cu (II) treated DNA 
DNA nucleotide/TC 
molar ratio 
Native DNA 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
1:12 
O.lMNaOH 
Acid soluble 
nucleotides 
0.0 
32.5 
55 
70 
75 
85 
95 
107 
115 
%DNA 
hydrolysis 
0.0 
13 
22 
28 
30 
34 
38 
43 
46 
0.5M NaOH 
Acid soluble 
nucleotides 
0.0 
35 
72.5 
85 
92.5 
102 
117 
122 
125 
%DNA 
hydrolysis 
0.0 
14 
29 
34 
37 
41 
47 
49 
50 
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Table 19 
Alkaline hydrolysis of oxytetracycline-Cu (II) treated DNA 
DNA nucleotide/TC 
molar ratio 
Native DNA 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
1:12 
O.lMNaOH 
Acid soluble 
nucleotide 
(Hg) 
0.0 
35 
72.5 
85 
95 
102.5 
112.5 
122.5 
132.5 
% DNA 
hydrolysis 
0.0 
14 
29 
34 
38 
41 
45 
49 
53 
0.5M NaOH 
Acid soluble 
nucleotide 
0.0 
40 
85 
100 
112 
125 
140 
150 
160 
% DNA 
hydrolysis 
0.0 
16 
34 
40 
45 
50 
56 
60 
64 
138 
Table 20 
Alkaline hydrolysis of doxycycline-Cu (II) treated DNA 
DNA nucleotide/DOTC 
molar ratio 
Native DNA 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
1:12 
O.lMNaOH 
Acid soluble %DNA 
nucleotide hydrolysis 
0.0 
50 
102 
122 
140 
150 
175 
190 
205 
0.0 
20 
41 
49 
56 
60 
70 
76 
82 
0.5 M NaOH 
Acid soluble 
nucleotide 
0.0 
55 
105 
125 
145 
162 
182 
197 
215 
% DNA 
hydrolysis 
0.0 
22 
42 
50 
58 
65 
73 
79 
86 
139 
Table 21 
Alkaline hydrolysis of demeclocycline-Cu (II) treated DNA 
DNA nucIeotide/DMTC 
molar ratio 
Native DNA 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
1:12 
O.lMNaOH 
Acid soluble 
nucleotides 
0.0 
32 
57 
70 
80 
87 
100 
107 
117 
% DNA 
hydrolysis 
0.0 
13 
23 
28 
32 
35 
40 
43 
47 
0.5M NaOH 
Acid soluble 
nucleotides 
0.0 
35 
72 
87 
97 
107 
120 
130 
139 
% DNA 
hydrolysis 
0.0 
14 
29 
35 
39 
43 
48 
52 
55 
o 
X 
o 
3 
•a 
c 
o 
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TC/DNA nucleotide molar ratio 
Figure 43. Fraction of duplex DNA recovered after treatment with 
increasing concentrations of tetracycline - Cu (II). The alkaline 
unwinding was carried out as described in methods. 
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on the amount of duplex DNA remaining after alkali treatment for specified time, 
the number of strand breaks formed per unit DNA were determined at 
corresponding tetracycline concentrations. A parallel control does not show any 
reduction in the amount of duplex DNA. However, at the highest DNA nucleotide-
TC molar ratio of 1:10, approximately 6.0 strand breaks per unit DNA were 
produced (Table 22). 
3.4. Hydroxyapatite chromatography of tetracycline treated DNA 
Figure 44 shows the elution profiles of DNA treated with increasing 
concentrations of tetracycline. The native DNA was eluted from the column at the 
phosphate molarity of 0.25 M (panel A). However, the DNA treated at a 
nucleotide-TC molar ratio of 1:5 emerged as a minor separate peak upon elution 
with 0.15 M phosphate buffer (panel B). At 1:10 molar ratio, the area of the peak 
eluting at 0.25 M decreased with a concomitant increase in the area of single 
stranded DNA peak eluting at 0.15 M phosphate buffer (panel C). Based on the 
absorbance of eluted DNA, an estimated 50% transformation of the double 
stranded DNA into single stranded form occurs at 1:10 molar ratio. 
3.5. Plasmid nicking assay 
Figure 45 (A & B) shows the agarose gel electrophoretic pattern of 
tetracycline treated plasmid pBR322 DNA. Treatment of supercoiled DNA (form 
I) with TC-Cu (II) at 1:1 molar ratio results in complete transformation to relaxed 
open circle (form II). Further increase in tetracycline concentrations up to 1 mM at 
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Table 22 
Tetracycline-Cu (II) induced strand breaks in calf thymus DNA 
DNA nucleotide/TC Fraction of duplex Number of breaks per 
molar ratio DNA (F) unit DNA (n) 
1:0 0.81 
1:1 0.60 1.42 
1:2 0.55 1.83 
1:4 0.44 2.89 
1:6 0.33 4.26 
1:8 0.24 5.76 
1:10 0.23 5.97 
o 
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Figure 44. Hydroxyapatite chromatography of tetracycline treated 
calf thymus DNA. (A) Control native DNA, (B) DNA treated at 
nucleotide - TC molar ratio of 1:5, (C) DNA treated at nucleotide 
-TC molar ratio of l.iO. 
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Figure 45. (A) Agarose gels electrophorogram of plasmid pBR322 DNA 
treated with increasing concentrations of tetracycline: Lane 1 control 
untreated DNA, lanes 2-8, DNA treated with 0.05, 0.1, 0.4, 0.6, 1.0, 1.5 and 
2.0 mM TC, respectively. 
(B) Electrophoretic pattern of plasmid pBR322 DNA treated with 100 |iM Cu 
(II) and increasing concentrations of tetracycline: Lane 1 Control untreated 
DNA, lane 2, DNA treated with 100 )LXM CU (II), lanes 3-8, DNA treated with 
0.05,0.1,0.2,0.4,0.6 and 1.0 mM TC plus 100 ^M Cu (II), respectively. 
(C) Electrophoretic pattern of plasmid pBR322 DNA treated with 100 |iM 
tetracycline and increasing concentrations of Cu (II) ions: Lane 1 Control 
untreated DNA, lane 2, DNA treated with 100 nM TC, lanes 3-8, DNA 
treated with 0.05, 0.1, 0.2, 0.4, 0.6 and 0.8 mM Cu (II) ions plus 100 ^M TC, 
respectively. 
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a constant concentration (100|iM) of Cu (II) does not bring any further change in 
form (II). Also the treatment with tetracycline alone does not induced any 
topological changes in the plasmid. However, increasing Cu (II) concentration 
from 0.1 to 1 mM at fixed tetracycline concentration results in linearization of 
relaxed plasmid species (Figure 45 C). Similar results were also obtained with the 
tetracycline derivatives viz. CTC, OTC, DOTC and DMTC (Figures 46). A 
noticeable reduction in the intensity of the band corresponding to covalently 
closed circular (CCC) form of plasmid DNA occurred with a concomitant increase 
in the amount of nicked species. Moreover, Figure 46 A (lane 5 and 6) shows that 
DOTC and DMTC at 1 mM concentration results in complete conversion of 
supercoiled form (form-I) to open circular form (form-II). In presence of 100 |iM 
Cu (II) ion, all the five derivatives of tetracycline caused complete conversion to 
open circular form (Figure 46 B). The plasmid nicking ability of the tetracycline 
derivatives was determined to be in the order as DOTC=DMTC>TC>OTC>CTC. 
3.6. Stoichiometry of tetracyclines-Cu(II) interactions and quantitation of 
Cu (I) production 
The Job plots shown in Figure 47 indicate the stoichiometry of tetracycline-
Cu (II) interaction. An increase in absorbance at 480 nm was noticed with 
increasing Cu (II)-TC ratios. The amount of Cu (I) produced in the reaction 
mixture forms complex with bathocuproine and absorbs maximally at 480 nm. The 
Cu (II) or tetracyclines alone does not interfere at this absorption maxima. A linear 
increase in the absorbance was observed up to 3.5:1 molar ratio of eq Cu (II)/TC 
Figure 46. (A) Electrophoretic pattern of plasmid pBR322 DNA treated with 
1.0 mM tetracycline and its derivatives without Cu (II). Lane-l Control 
untreated DNA, lanes 2-6, DNA treated with TC, OTC, CTC. DOTC and 
DMTC, respectively. 
(B) Electrophoretic pattern of plasmid pBR322 DNA incubated with 100 jiM 
Cu (II) and 1.0 mM of TC and its derivatives. Lane-l, Control untreated 
DNA. lane 2, 100 ^M Cu (II), lane 3, Cu (II) + TC, lane 4 Cu (II) + OTC, 
lane 5 Cu (II) + CTC, lane 6 Cu (II) + DOTC, and lane 7, Cu (B) + DMTC. 
The positions of form I, II and III DNA species are indicated. 
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Figure 47. Stoichiometry of Cu (H) - tetracycline binding at concentrations 
(-0-) 12.5 liMTC and (-#-)25 \lMTC. The difference in absorbance 
at 480 nm of the samples with and without added Cu (II) is plotted versus 
molar equivalents ofCu(ir) per molar equivalent TC. The value of the 
independent variable at the intersection of the two lines is a measure of the 
ratio of Cu (IT) to TC. Both curves correspond to 3.5 equivalents Cu (IT) 
to 1 equivalent TC. 
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and reaches to a plateau at higher Cu (II)-TC molar ratios. Similar studies were 
also performed with tetracycline derivatives and the results are shown in Figure 48 
(A-D). The amounts of Cu (I) produced are shown in Tables 23-27. The 
spectroscopic data in Figure 49 A and B with tetracycline-Cu (II) in combination 
with the neocuproine and bathocuproine clearly indicate the production of Cu (I) 
upon tetracycline-Cu (II) interaction. A significant absorption of Cu (I)-
neocuproine complex at 450 nm was observed compared to tetracycline-
neocuproine and cu (Il)-neocuproine complexes. Also, substantial enhancement in 
the absorbance at 450 nm was noticed with TC-Cu (Il)-neocuproine complex. 
Similar absorption pattern was obtained with tetracycline-Cu (II) interaction in 
presence of bathocuproine at 480 nm. 
2 4 6 
Eq Cu (H)/CTC 
2 4 6 
Eq Cu (ll)/OTC 
2 4 6 
Eq Cu {ll)/DOTC 
2 4 
Eq Cu (ll)/DMTC 
Figure 48. Stoichiometry Of Cu (II)-tetracycIine derivatives binding at concentrations 
(-0-) 12.5 fiM and (-•-) 25 i^M of (A) CTC, (B) OTC, (C) DOTC and (D) DMTC, 
respectively. The difference in absorbance at 480 nm of the samples with and without 
added Cu (II) is plotted versus molar equivalents of Cu (II) per molar equivalent 
tetracycline derivatives. The value of the independent variable at the intersection of 
two lines is a measure of the ratio of Cu (II) to tetracycline derivatives. 
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Table 23 
Production of Cu I) upon tetracycline-Cu (II) interaction 
Cu (II) 
0.0 
3.125 
6.25 
12.5 
18.75 
25.0 
31.25 
37.50 
43.75 
50.0 
56.25 
62.50 
75.0 
87.50 
100.0 
112.5 
125.0 
137.5 
added (|JM) 
Cu (I) produced (|xM)* 
TC (12.5 ^M) 
0.0 
0.370 
1.185 
2.296 
3.407 
5.037 
6.00 
7.111 
8.222 
8.148 
8.074 
8.296 
8.222 
ND 
ND 
ND 
ND 
ND 
TC (25 ^M) 
0.0 
ND 
0.741 
2.296 
ND 
4.741 
ND 
6.518 
ND 
8.963 
ND 
11.037 
13.926 
16.370 
16.592 
16.444 
16.370 
16.370 
* Concentration of Cu (I) were calculated by using the equation A= eel in which molar 
absorptivity (€) of Cu (bathocuproine)2"^  complex = 13500 and path length (1) = 1 cm, 
A A480 was obtained from A480 of the sample with and without Cu (II) addition. 
ND, not done. 
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Table 24 
Production of Cu (I) upon chlorotetracycline-Cu (II) interaction 
Cu(II) added (^M) 
0.0 
3.125 
6.25 
12.5 
18.75 
25.0 
31.25 
37.50 
43.75 
50.0 
56.25 
62.50 
75.0 
87.50 
100.0 
112.5 
125.0 
137.5 
Cu (I) produced (JJM)* 
CTC (12.5 ^M) 
0.0 
0.74 
1.11 
2.22 
3.70 
4.82 
5.56 
7.04 
8.52 
9.78 
9.26 
9.63 
9.70 
ND 
ND 
ND 
ND 
ND 
CTC (25 ^M) 
0.0 
ND 
1.48 
2.22 
ND 
4.60 
ND 
7.11 
ND 
8.89 
ND 
10.37 
14.15 
15.56 
18.15 
18.52 
18.15 
18.10 
*Concentration of Cu(I) were calculated by using the equation A= eel in which molar 
absorptivity(e) of Cu (bathocuproine)2^ complex = 13500 and path length (1) = 1 cm, 
A A480 was obtained from A4go of the sample with and without Cu(II) addition. 
ND, not done. 
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Table 25 
Production of Cu (I) upon oxytetracycline-Cu (II) interaction 
Cu (II) added (^M) 
0.0 
3.125 
6.25 
12.5 
18.75 
25.0 
31.25 
37.50 
43.75 
50.0 
56.25 
62.50 
75.0 
87.50 
100.0 
112.5 
125.0 
137.5 
Cu (I) produced (fiM)* 
OTC (12.5 nM) 
0.0 
1.48 
1.85 
3.34 
4.67 
6.30 
7.11 
9.26 
10.44 
11.85 
12.0 
11.85 
11.12 
ND 
ND 
ND 
ND 
ND 
OTC (25 \iM) 
0.0 
ND 
2.22 
3.33 
ND 
6.67 
ND 
10.37 
ND 
13.71 
ND 
17.26 
19.26 
22.59 
26.15 
25.93 
25.56 
26.00 
*Concentration of Cu (I) were calculated by using the equation A= eel in which molar 
absorptivity (e) of Cu (bathocuproine)2^ complex = 13500 and path length (1) = 1 cm, 
A A480 was obtained from A480 of the sample with and without Cu(II) addition. 
ND, not done. 
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Table 26 
Production of Cu(I) upon doxycycline-Cu (II) interaction 
Cu (II) added (^M) 
0.0 
3.125 
6.25 
12.5 
18.75 
25.0 
31.25 
37.50 
43.75 
50.0 
56.25 
62.50 
75.0 
87.50 
100.0 
112.5 
125.0 
137.5 
Cu (I) produced ()uM)* 
DOTC (12.5 
0.0 
2.67 
6.00 
10.37 
17.18 
22.30 
22.96 
22.96 
21.95 
22.15 
22.30 
22.96 
22.96 
ND 
ND 
ND 
ND 
ND 
^M) DOTC (25 ^M) 
0.0 
ND 
5.78 
11.78 
ND 
21.34 
ND 
32.22 
ND 
42.44 
ND 
42.96 
42.37 
41.56 
42.45 
41.85 
42.59 
42.44 
*Concentration of Cu(I) were calculated by using the equation A= eel in which molar 
absorptivity (e) of Cu (bathocuproine)2"^  complex = 13500 and path length (1) = 1 cm, 
A A480 was obtained from A480 of the sample with and without Cu(II) addition. 
ND, not done. 
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Table 27 
Production of Cu (I) upon demeclocycline-Cu (II) interaction 
"(:u (II) added (^M) Cu (I) produced (^iM)" 
DMTC (12.5 i^M) 
0.0 
2.0 
5.33 
10.44 
13.41 
12.67 
13.33 
12.96 
13.26 
13.56 
13.41 
13.33 
ND 
ND 
ND 
ND 
ND 
DMTC (25 ^M) 
0.0 
ND 
4.15 
8.60 
ND 
16.15 
ND 
22.67 
ND 
22.59 
ND 
22.22 
22.96 
22.59 
22.74 
22.37 
22.22 
0.0 
3.125 
6.25 
12.5 
18.75 
25.0 
31.25 
37.50 
43.75 
50.0 
56.25 
62.50 
75.0 
87.50 
100.0 
112.5 
125.0 
*Concentration of Cu(I) were calculated by using the equation A= eel in which molar 
absorptivity (G) of Cu (bathocuproine)2^ complex = 13500 and path length (1) = 1 cm, 
A A480 was obtained from A480 of the sample with and without Cu(II) addition. 
ND, not done. 
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Figure 49. (A) Detection of tetracycline-induced Cu (I) 
production by neocuproine.The curves represents as (- • • • -) 
neocuproine + Cu (II) (100 jiM); (- • -) neocuproine + Cu (I) (10 
HM); (-) TC (50 nM) + neocuproine; ( ) TC (50 ^M) + Cu 
(II) (100 \iM) + neocuproine. Neocuproine (100 fiM) was added 
after the mixing of TC and Cu (II). 
(B). Detection of tetracycline-induced Cu (I) production by 
bathocuproine. The curves represents as (- • • • -) bathocuproine 
+ Cu (H) (100 iiM); (- • -) bathocuproine + Cu (I) (10 \M); (-) 
TC (50 fiM) + bathocuproine; ( ) TC (50 ^M) + Cu (II) (100 
^M) + bathocuproine. Bathocuproine (100 fiM) was added after 
the mixing of TC and Cu (II). 
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4. Discussion 
The present study demonstrates the reactivity of tetracyclines with DNA, 
and role of Cu (II) in inducing DNA strand breakage. The proposed schemes I and 
II in Figure 50 present the plausible mechanism of tetracycline-Cu (II) interaction 
with DNA. The suggested mechanism revealed tetracycline-Cu (II) catalyzed 
chain scission due to possible alkylation of nitrogenous bases. Most likely, the TC-
Cu (II) induced damage in DNA occurs due to the (i) strong interaction resulting 
in the formation of TC-Cu (II)-DNA ternary complex, and (ii) formation of 
tetracyclines-induced free radicals in vicinity of DNA backbone. The formation of 
ternary complex induces conformational change in DNA leading to helix transition 
due to local unwinding. This tetracycline-Cu (II) catalyzed denaturation of native 
duplex DNA has been demonstrated by hydroxyapatite chromatography. It is 
known that subtle differences in the secondary and tertiary structures of nucleic 
acids could be easily discriminated by this technique based on differential 
distribution of phosphate groups available on DNA for interaction with the 
adsorbing sites on hydroxyapatite column (Bemardi, 1971). Also the alkaline 
unwinding assay using hydroxyapatite as a matrix for DNA binding suggested the 
formation of ~ 6 strand breaks per DNA molecule. The assay is based on the 
observation that the DNA molecule when exposed to alkaline conditions beyond 
the helix-coil transition range (pH>11.5) will undergo strand separation i.e. 
unwinding at each formal strand break (Daniel et ai, 1985) under controlled 
experimental conditions. The amount of duplex DNA remaining after a given 
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Figure 50. Scheme I : Mechanism of interaction of tetracycIine-Cu (II) with GC 
base pair in DNA. 
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period of alkaline unwinding will be inversely proportional to the number of 
strand breaks at the initiation of the alkaline procedure. 
The formation of tetracycline-induced single stranded regions in DNA may 
also be due to transfer of methyl groups from tetracyclines to nitrogenous bases. 
Tetracycline contains one methyl group at C-6 on the ring-C and two methyl 
groups on nitrogen atom at C-4 of the ring-A. Most likely, the methyl groups 
(electrophiles) of the activated site (scheme II and I) are released and captured by 
N-7 and N-3 (nucleophilic positions) of the guanine and adenine. Since the N-7 
position on purine ring is the most preferred site for methylation, base 
modification at this site does not perturb the aromatic character. However, the 
aromatic character of the molecule will be compromised, in case methylation 
occurs at N-3 position, and possibly the modified bases will undergo 
tautomerization. The alkylation of bases is known to perturb the normal base 
pairing potential and cause changes in configuration of the phosphate backbone, 
which ultimately results in the destabilisation of the secondary structure of DNA. 
Earlier studies also suggest that partial denaturation of alkylated DNA occurs at 
higher pH through the disruption of hydrogen bonding due to a base catalyzed 
imidazole ring opening of the quartemized N-7 guanine. It is also reported that the 
alkylation leads to DNA denaturation under neutral conditions (Wani et al, 1978). 
At neutral pH, TC-Cu (II) is reported to form complex at two possible sites 
(Albert, 1985; Martin, 1986). At least, one Cu (II) ion form complex with the 
oxygen at C3 and the oxygen of the amide group and another forms an additional 
complex with the oxygen at C-10 and C-11 positions on tetracycline molecule. 
160 
Addition of Cu (II) ions leads to the generation of an electrophile at C-4 position 
of the tetracychne. Since N-methyl group of tetracychne at carbon position 4 is 
relatively more labile, it may preferentially interact with N-7 and N-3 position of 
purine (adenine and guanine) bases of DNA without much steric hindrance. The 
methylation at these site on guanine and adenine will result in GC to AT and AT 
to GC mispairing and also the formation of apurinic/apyrimidinic sites in TC-Cu 
(II) treated DNA (scheme I and II). Studies with the Cu (I) specific chelating 
agents neocuproine and bathocuproine revealed that the tetracycline-Cu (II) 
interactions results in the reduction of Cu (II) to Cu (I). Neocuproine forms 
complexes with Cu (I) to yield Cu (neocuproine)2^ complex, which has an 
absorption peak at 450 nm (Nebesar, 1964). However, bathocuproine forms an 
intense orange coloured complex with Cu (I), which absorbs maximally at 480 nm 
(Joselow & Dawson, 1951). 
Susceptibility of treated DNA to alkaline hydrolysis also suggests 
tetracycline-Cu (II) induced DNA alkylation and creation of apurinic and/or 
apyrimidinic sites on the DNA molecule. The phosphodiester bond cleavage near 
each apurinic site produces acid-soluble material upon alkaline hydrolysis (Tamm 
et al, 1953). Thus, the release of acid soluble material from TC-treated DNA 
confirmed the formation of apurinic and/or apyrimidinic sites in the DNA 
molecule. It is reported that the purine residues methylated at N-3 and N-7 
positions, are released at an accelerated rate (Lawley & Warren, 1976). The 
increased hydrolysis of alkylated DNA with 0.5 M NaOH suggests the formation 
of both the apurinic sites as well as phosphotriesters. These results are in 
1 6 1 
agreement with the earUer studies demonstrating that the DNA hydrolysis with 0.1 
M and 0.5 M NaOH possibly discerns the apurinic sites and phosphotriesters 
(Shooter & Merrifield, 1976). Induction of single-strand breaks and alkali labile 
sites have also been reported in DNA treated with the alkylating agents N-
nitrosourea (Su et ai, 1983). 
The perturbations in DNA secondary structure was further substantiated by 
plasmid nicking assay. The transformation of covalently closed circular (CCC-
form I) plasmid DNA into nicked (form-II) and linear (form-Ill) species with 
increasing tetracycline concentration clearly suggest strand breakage in 
tetracycline-Cu (II) treated plasmid DNA. This is consistent with earlier studies 
showing induced DNA breakage in bacteriophage PM2 and Ml3 DNA (Mhaskar 
et al, 1981; Piette et al, 1986; Quinlan & Gutteridge, 1991; Buschfort & Witte, 
1994) with TC in combination with Cu (II), possibly due to free radicals 
generation. Earlier studies suggested that the generation of oxygen radicals in 
proximity of DNA backbone is a potential cause of strand scission (Graham et al., 
1981; Eliot et al, 1984; Wong et al, 1984; Chu & Orgel, 1985; Dreyer & Dervan, 
1985; Goldstein & Czapski, 1986). The antibiotics such as methicillin, bacitracin, 
rifamycin and tetracyclines have been shown to undergo oxidation and in the 
presence of transition metal ions such as iron and copper leads to the formation of 
highly reactive oxygen species (Tamm et al, 1953; Khan & Musarrat, 2001). Most 
likely, the tetracyclines in reduced form (TCH2) under goes oxidation with a 
transfer of electron to either molecular oxygen to form superoxide (02~) or to 
transition metal ion such as copper (equation 1 and 2). The superoxide anions 
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generated can act both as a reductant for transition metal ions or as a precursor of 
hydrogen peroxide (equation 3). Finally, the Fenton-type reaction forms OH 
radicals due to reaction of reduced copper with hydrogen peroxide (equation 4) 
leading to DNA damage. 
TCH2 (reduced) + 2O2 ^ TC (oxidized) + 2O2 • ~ + 2H^ (1) 
TCH2 (reduced) + 2Cu^ ^ • TC (oxidized) + 2CuV 2H+ (2) 
202-" + 2H^ • H2O2+ O2 (3) 
- • Cu^  + H202 Cu^ ^ + -OH+'OH (4) 
- • 
•OH + DNA DNA damage (5) 
The reactive oxygen species generated from Fenton-type reaction have been 
reported to cause site-specific cleavage in DNA (Buschfort & Witte, 1994). The 
proposed tetracycline-induced DNA strand cleavage mainly occurs in the presence 
of Cu (II). Studies involving the free radical quenchers such as sodium benzoate 
and mannitol clearly suggested the role of 'OH radicals in tetracycline-Cu (II) 
induced DNA damage. Thus a combined damaging effect of tetracycline-Cu (II) 
induced base alkylation and free radicals on DNA is suggested. The tetracycline-
Cu (II) induced structural alteration and strand breakage as demonstrated in vitro 
may also pose a serious health risk under intracellular conditions. Any defects in 
cellular DNA repair pathway may result in base mismatch as also evident from the 
proposed mechanism in scheme I and II. Thus an imperfect repair of tetracycline-
Cu (II) induced damaged DNA may lead to genotoxicity and mutagenesis. 
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